

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
19 August 2004 (19.08.2004)

PCT

(10) International Publication Number  
**WO 2004/069152 A2**

(51) International Patent Classification<sup>7</sup>: **A61K**

(21) International Application Number:  
PCT/US2003/013938

(22) International Filing Date: 5 May 2003 (05.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/377,488 3 May 2002 (03.05.2002) US

(71) Applicant: **MASSACHUSETTS INSTITUTE OF TECHNOLOGY** [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US).

(72) Inventors: **MYETTE, James, R.**; 379 Belmont Street, Belmont, MA 02479 (US). **SHRIVER, Zachary**; 26 Inman Street #3C, Cambridge, MA 02139 (US).

**VENKATARAMAN, Ganesh**; 111 Locust #1702, Woburn, MA 01801 (US). **SASISEKHARAN, Ram**; 2130 Massachusetts Avenue #7B, Cambridge, MA 02140 (US). **MCLEAN, Maitland, W.**; Nisthouse Harray, Orkney KW17 2KQ (GB).


(74) Agent: **LOCKHART, Helen, C.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title:  $\Delta$ 4,5 GLYCURONIDASE AND USES THEREOF



A



B

PEAK NO.	PEPTIDE SEQUENCE
8	EPNKPWFDAAK
12	PGENQPFILK
13	FTLALDTIQYVK
19	VLQRETHQGLINESAWARGQAWGLGYTMSYK
24	HSVGAALLYNSEIDTPELYADYYYLEALK
26	TAVIQLTRAAQYTPGMNPRSVNPDGTVRLAPPR

C

(57) Abstract: The invention relates to  $\Delta$ 4,5 glycuronidase, related compositions, and methods of use thereof.



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

## **Δ 4, 5 GLYCURONIDASE AND USES THEREOF**

### **FIELD OF THE INVENTION**

The invention relates to Δ4, 5 glycuronidase and uses thereof. In particular, the invention relates to substantially pure Δ4, 5 glycuronidase which is useful for a variety of purposes, including analysis of glycosaminoglycans (GAGs), sequencing, identifying, quantifying and purifying glycosaminoglycans present in a sample, removing glycosaminoglycans, such as heparin, from a solution and inhibiting angiogenesis, controlling coagulation, etc. The invention also relates to methods of treating cancer and inhibiting cellular proliferation and/or metastasis using Δ4, 5 glycuronidase and/or GAG fragments produced by enzymatic cleavage with Δ4, 5 glycuronidase.

### **BACKGROUND OF THE INVENTION**

Glycosaminoglycans (GAGs) are linear, acidic polysaccharides that exist ubiquitously in nature as residents of the extracellular matrix and at the cell surface of many different organisms of divergent phylogeny [Habuchi, O. (2000) *Biochim Biophys Acta* 1474, 115-27; Sasisekharan, R., Bulmer, M., Moremen, K. W., Cooney, C. L., and Langer, R. (1993) *Proc Natl Acad Sci USA* 90, 3660-4]. In addition to a structural role, GAGs act as critical modulators of a number of biochemical signaling events [Tumova, S., Woods, A., and Couchman, J. R. (2000) *Int J Biochem Cell Biol* 32, 269-88] requisite for cell growth and differentiation, cell adhesion and migration, and tissue morphogenesis.

Heparan sulfate like glycosaminoglycans (GAGS or HSGAGs) are present both at the cell surface and in the extracellular matrix. Heparin-like glycosaminoglycans are important components of the extracellular matrix that are believed to regulate a wide variety of cellular activities including invasion, migration, proliferation and adhesion (Khodapkar, et al. 1998; Woods, et al., 1998). HSGAGs accomplish some of these functions by binding to and regulating the biological activities of diverse molecules, including growth factors, morphogens, enzymes, extracellular proteins. HSGAGs are a group of complex polysaccharides that are variable in length, consisting of a disaccharide repeat unit composed of glucosamine and an uronic acid (either iduronic or glucuronic acid). The high degree of complexity for HSGAGs arises not only from their polydispersity and the possibility of two different uronic acid components, but also from differential modification at four positions of the disaccharide unit. Three positions, viz.,

-2-

C2 of the uronic acid and the C3, C6 positions of the glucosamine can be O-sulfated. In addition, C2 of the glucosamine can be N-acetylated or N-sulfated. Together, these modifications could theoretically lead to 32 possible disaccharide units, making HSGAGs potentially more information dense than either DNA (4 bases) or proteins (20 amino acids). It is this enormity of possible structural variants that allows HSGAGs to be involved in a large number of diverse biological processes, including angiogenesis (Sasisekharan, R., Moses, M. A., Nugent, M. A., Cooney, C. L. & Langer, R. (1994) *Proc Natl Acad Sci U S A*, 1524-8.), embryogenesis (Binari, R. et al (1997) *Development*, 2623-32; Tsuda, M., et al. (1999) *Nature*, 276-80.; and Lin, X., et al (1999) *Development*, 3715-23.) and the formation of  $\beta$ -fibrils in Alzheimer's disease (McLaurin, J., et al (1999) *Eur J Biochem*, 1101-10. and Lindahl, B., et al (1999) *J Biol Chem*, 30631-5).

One specific example of an HSGAG is heparin. Heparin, a highly sulphated HSGAG produced by mast cells, is a widely used clinical anticoagulant, and is one of the first biopolymeric drugs and one of the few carbohydrate drugs. Heparin primarily elicits its effect through two mechanisms, both of which involve binding of antithrombin III (AT-III) to a specific pentasaccharide sequence,  $H_{NAc/S,6S}GH_{NS,3S,6S}I_{2S}H_{NS,6S}$  contained within the polymer. HSGAGs have also emerged as key players in a range of biological processes that range from angiogenesis [Folkman, J., Taylor, S., and Spillberg, C. (1983) *Ciba Found Symp* 100, 132-49] and cancer biology [Blackhall, F. H., Merry, C. L., Davies, E. J., and Jayson, G. C. (2001) *Br J Cancer* 85, 1094-8] to microbial pathogenesis [Shukla, et al (1999) *Cell* 99, 13-22]. HSGAGs have also recently been shown to play a fundamental role in multiple aspects of development [Perrimon, N. and Bernfield, M. (2000) *Nature* 404, 725-8]. The ability of HSGAGs to orchestrate multiple biological events is again likely a consequence of its structural complexity and information density [Sasisekharan, R. and Venkataraman, G. (2000) *Curr Opin Chem Biol* 4, 626-31].

Although the structure and chemistry of HSGAGs are fairly well understood, information on how specific HSGAG sequences modulate different biological processes has proven harder to obtain. Determination of these HSGAG sequence has been technically challenging. HSGAGs are naturally present in very limited quantities, which, unlike other biopolymers such as proteins and nucleic acids, cannot be readily amplified. Second, due to their highly charged character and structural heterogeneity, HSGAGs are

-3-

not easily isolated from biological sources in a highly purified state. Additionally, the lack of sequence-specific tools to cleave HSGAGs in a manner analogous to DNA sequencing or restriction mapping has made sequencing a challenge.

Recently, in an effort to develop an understanding of HSGAG structure, focus  
5 has been placed on the cloning and characterization of the enzymes involved in HSGAG biosynthesis. Another, strategy for elucidating the structure of HSGAGs has been to employ specific HSGAG degradation procedures, including chemical or enzymatic cleavage, in conjunction with analytical methodologies, including gel electrophoresis or HPLC, to sequence HSGAGs. Recently, we have introduced a sequencing procedure  
10 that couples a bioinformatics framework with mass spectrometric and capillary electrophoretic procedures to sequence rapidly biologically important HSGAGs, including saccharide sequences involved in modulating anticoagulation. The sequencing methodology uses chemical and enzymatic tools to modify or degrade an unknown glycosaminoglycan polymer in a sequence-specific manner. (Venkataraman, G., et al.,  
15 *Science*, 286, 537-542 (1999), and U.S. Patent Applications Serial Nos. 09/557,997 and 09/558,137, both filed on April 24, 2000, having common inventorship).

#### SUMMARY OF THE INVENTION

$\Delta$ 4, 5 glycuronidase has been cloned from the *F. heparinum* genome and its subsequent recombinant expression in *E. coli* as a soluble, highly active enzyme has been  
20 accomplished. Thus, in one aspect the present invention provides for a substantially pure  $\Delta$ 4,5 glycuronidase. In one embodiment of the invention the substantially pure  $\Delta$ 4,5 glycuronidase is a recombinantly produced glycuronidase. Recombinant expression may be accomplished in one embodiment with an expression vector. An expression vector may be a nucleic acid for SEQ ID NO:2, optionally operably linked to a promoter. In another  
25 embodiment the expression vector may be a nucleic acid for SEQ ID NO:4 or a variant thereof also optionally linked to a promoter. In one embodiment the substantially pure  $\Delta$ 4,5 glycuronidase is produced using a host cell comprising the expression vector. In another embodiment the substantially pure  $\Delta$ 4,5 glycuronidase is a synthetic glycuronidase.

30 In another aspect the glycuronidase of the invention is a polypeptide having an amino acid sequence of SEQ ID NO:1, or a functional variant thereof. In yet another

-4-

aspect the polypeptide has an amino acid sequence of SEQ ID NO:3, or a functional variant thereof.

In yet another aspect of the invention the polypeptide of the  $\Delta 4,5$  glucuronidase is an isolated polypeptide. The isolated polypeptide in some embodiments is set forth in  
5 SEQ ID NO:1 or is a functional variant thereof. In other embodiments the isolated polypeptide is set forth in SEQ ID NO:3 or a functional variant thereof.

In one aspect, the invention is a composition comprising, an isolated  $\Delta 4,5$  unsaturated glucuronidase having a higher specific activity than native glucuronidase. In some embodiments, the specific activity is at least about 60 picomoles of substrate  
10 hydrolyzed per minute per picomole of enzyme. In one embodiment the  $\Delta 4,5$  glucuronidase has a specific activity that is about 2 fold higher than the native enzyme. In another embodiment the  $\Delta 4,5$  glucuronidase has a specific activity that is about 3 fold higher. The specific activity of the  $\Delta 4,5$  glucuronidase in other embodiments may be about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55,  
15 60, 65, 70, 75, 80, 85, 90, 95, 100 or any integer therebetween fold higher than the activity of the native enzyme.

In yet another aspect of the invention an isolated nucleic acid molecule is provided. The nucleic acid is (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID  
20 NO:2 or SEQ ID NO:4, and which code for  $\Delta 4,5$  unsaturated glucuronidase having an amino acid sequence set forth as SEQ ID NO:1 or SEQ ID NO:3, respectively, (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code, or (c) complements of (a) or (b). In one embodiment the isolated nucleic acid molecule codes for SEQ ID NO:1. In another  
25 embodiment the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:2. In still other embodiments the isolated nucleic acid molecule codes for SEQ ID NO:3 and in yet other embodiments the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:4.

Pharmaceutical compositions of any of the compositions or vectors described  
30 herein are also encompassed in the invention.

In other aspects the invention relates to a method of cleaving a glycosaminoglycan with a  $\Delta 4,5$  unsaturated glucuronidase. The method may be

-5-

performed by contacting a glycosaminoglycan with the glycuronidase in an effective amount to cleave the glycosaminoglycan. In one embodiment the invention is a glycosaminoglycan prepared according to this method.

In other aspects the invention also provides a method of cleaving a glycosaminoglycan comprised of at least one disaccharide unit. The method may be performed by contacting the glycosaminoglycan with a glycuronidase of the invention in an effective amount to cleave the glycosaminoglycan. In some embodiments the glycosaminoglycan is a long chain saccharide. In other embodiments the glycosaminoglycan does not contain a 2-0 sulfated uronate or it does not contain N-substituted glycosamine. In yet another embodiment the glycosaminoglycan is 6-0 sulfated. The disaccharide units in some embodiments are  $\Delta\text{UH}_{\text{NAc}}$ ;  $\Delta\text{UH}_{\text{NAc},6\text{S}}$ ;  $\Delta\text{UH}_{\text{NS},6\text{S}}$ ; or  $\Delta\text{UH}_{\text{NS}}$ . In another embodiment the invention also provides for the products of the cleavage of a glycosaminoglycan with the  $\Delta 4,5$  glycuronidase. In some embodiments the glycuronidase is used to generate a LMWH.

The present invention also provides methods for the analysis of glycosaminoglycan. In one aspect the invention is a method of analyzing a glycosaminoglycan by contacting a glycosaminoglycan with the glycuronidase of the invention in an effective amount to analyze the glycosaminoglycan. In one embodiment the method is a method for identifying the presence of a particular glycosaminoglycan in a sample. In another embodiment the method is a method for determining the identity of a glycosaminoglycan in a sample. In yet another embodiment the method is a method for determining the purity of a glycosaminoglycan in a sample. In still a further embodiment the method is a method for determining the composition of a glycosaminoglycan in a sample. In another embodiment the method is a method for determining the sequence of saccharide units in a glycosaminoglycan. In other embodiments, these methods may also comprise an additional analytical technique such as mass spectrometry, gel electrophoresis, capillary electrophoresis and HPLC. In some embodiments the glycosaminoglycan is LMWH.

In other aspects the invention is a method of removing heparin from a heparin containing fluid by contacting a heparin containing fluid with a glycuronidase of the invention in an effective amount to remove heparin from the heparin containing fluid. In one embodiment the glycuronidase is immobilized on a solid support. In another

-6-

embodiment a heparinase is also provided and the heparinase is also immobilized on the solid support.

In another aspect the invention is a method of inhibiting angiogenesis by administering to a subject in need thereof an effective amount of any of the pharmaceutical preparations described herein for inhibiting angiogenesis.

In another aspect a method of treating cancer by administering to a subject in need thereof an effective amount of any of the pharmaceutical preparations described herein for treating cancer is also provided.

Yet another aspect of the invention is a method of inhibiting cellular proliferation by administering to a subject in need thereof an effective amount of any of the pharmaceutical preparations described herein for inhibiting cellular proliferation.

In another aspect a method of treating a coagulation disease by administering to a subject in need thereof a LMWH prepared using the glycuronidase of the invention.

In some embodiments of the methods of the invention the glycuronidase is used concurrently with or following treatment with heparinase.

In other aspects of the invention, the pharmaceutical compositions and therapeutic methods are provided using the  $\Delta 4,5$  unsaturated glycuronidase and the cleaved GAG fragments alone or in combination.

Other aspects of the invention provide compositions that include other enzymes such as heparinase with the  $\Delta 4,5$  unsaturated glycuronidase.

In other aspects a pharmaceutical preparation of a composition or vector of the invention in a pharmaceutically acceptable carrier is provided.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

#### **BRIEF DESCRIPTION OF THE FIGURES**

**Figure 1** depicts the purification of  $\Delta 4, 5$  glycuronidase from *Flavobacterium* and resultant proteolysis. **A.** Gel filtration chromatography of the purified enzyme. **B.** Purification of  $\Delta 4, 5$  peptides by reverse phase HPLC following trypsinization of the native protein. **C.** Amino acid sequence of select peptides isolated in **B.** Peaks 8, 12, 13, 19, 24 and 26 are SEQ ID NOs: 18-23, respectively.



-7-

**Figure 2** provides a schematic map of  $\Delta 4, 5$  genomic clones. **A.** Partial carboxy-terminal clones G5A and G5H (black arrows) were isolated by hybridization screening of a  $\lambda$ ZAP Flavobacterial library using probes 1 and 2, respectively. Also shown is the Eco R1 restriction site delimiting the 5' end of G5A. **B.** Strategy to obtain the  $\Delta 4, 5$  5' terminus by Southern hybridization. Shown are the autoradiogram and its corresponding restriction map. Genomic DNA was restricted with Eco R1 alone (lane 1) or as a double digest with Hind III (lane 2), Bam H1 (lane3), or Bgl II (lane 4), respectively. DNA hybridization probe 3 used was amplified by PCR using N-terminal primers 68 and 74, both of which are 5' to the Eco R1 site. The Bgl II-Eco R1 ~1.5 kb DNA fragment (gray bar) was isolated for subcloning and DNA sequencing. **C.** Schematic representation of the full-length  $\Delta 4, 5$  gene (1.2 kb) compiled from overlapping clones shown in **A.** and **B.**

**Figure 3** depicts the  $\Delta 4, 5$  glycuronidase gene sequence. Full-length gene was isolated using methods outlined in Figure 2. The amino acid and nucleic acid sequences are given in SEQ ID NOS: 3 and 4, respectively. Shown here are both the coding and flanking DNA sequences. The CDS (coding sequence) of 1209 base pairs contains an ORF encoding a putative protein of 402 amino acids. Initiation and termination codons are highlighted in bold. A possible Shine-Dalgarno (SD) sequence is boxed. The presumed signal sequence is underlined and its cleavage site delimited by a vertical arrow. The Eco R1 restriction site is double-overscored. Also shown are the degenerate primer pairs (shown as arrows) used to PCR amplify DNA hybridization probes 1 and 2 as well as the relative positions of purified  $\Delta 4, 5$  peptides (shaded in gray) for which direct sequence information was obtained.

**Figure 4** illustrates the  $\Delta 4, 5$  glycuronidase primary sequence analyses. **A.** Hydropathy plot (Kyte-Doolittle). Positive values represent increasing hydrophobicity. **B.** Theoretical signal sequence determination using amino acids 1-65. Indices were calculated using SignalP V.1.1 using networks trained on gram-negative bacteria. Putative cleavage site located between G20 and M21 is represented by a vertical arrow. **C.** CLUSTAL W multiple alignment of full-length  $\Delta 4, 5$  glycuronidase with select glucuronyl hydrolases. Protein sequences were selected from an initial BLASTP search of the protein database. Identical amino acids are shaded in dark gray, near invariant positions in charcoal, and conservative substitutions in light gray. Gen Bank accession numbers are as follows: *Bacillus* sp. (AB019619); *Streptococcus pneumoniae*

-8-

(AE008410); *Streptococcus pyogenes* (AE006517); *Agaricus bisporus* (AJ271692); *Bactobacillus halodurans* (AP001514).

**Figure 5** provides results of recombinant  $\Delta 4,5^{\Delta 20}$  protein expression and purification. The amino acid and nucleic acid sequences are given as SEQ ID NOS: 1 and 2, respectively. SDS-PAGE of  $\Delta 4, 5$  protein fractions at various purification stages following expression in BL21 (DE3) as a 6XHIS N-terminal fusion protein. Shown here is a 12% gel that is stained with Coomassie-Brilliant blue. Lane 2, lysate from uninduced bacterial cells; Lane 3, crude cell lysate from induced cultures; Lane 4,  $\text{Ni}^{+2}$  chelation chromatography purification; Lane 5, thrombin cleavage to remove N-terminal 6X His purification tag. Molecular weight markers (Lanes 1 and 6) are also noted.

**Figure 6** depicts the effects of  $\Delta 4, 5$  glycuronidase biochemical reaction conditions. **A.** [NaCl] titration; **B.** Effect of reaction temperature **C.** pH profile. Relative enzyme activities were derived from the initial rates normalized to 100 mM NaCl (**A**) or 30°C (**C**).  $k_{\text{cat}}$  and  $K_m$  values for the pH profile were extrapolated from Michaelis-Menten kinetics as described in the Methods (and **Figure 8**) The disulfated heparin disaccharide  $\Delta\text{UH}_{\text{NS},6\text{S}}$  was used in all three experiments.

**Figure 7** depicts a kinetic comparison of native and recombinant enzymes. Relative specific activities were measured for both enzyme fractions under identical reaction conditions that included 200 nM enzyme and 500  $\mu\text{M}$  of the heparin disaccharide substrate ( $\Delta\text{UHNac}$ ). Flavobacterial  $\Delta 4, 5$  (closed circles); recombinant  $\Delta 4, 5$  (open circles).

**Figure 8** illustrates disaccharide substrate specificity. **A.** Kinetic profiles for heparin disaccharides of varying sulfation. Initial rates were determined using 200 nM enzyme under standard conditions.  $V_o$  vs.  $[S]$  curves were fit to Michaelis-Menten steady state kinetics using a non-linear least squares analysis. **B.** Lineweaver-Burke representation of the data shown in **A.**  $\Delta\text{UH}_{\text{Nac},6\text{S}}$  ( $\lambda$ );  $\Delta\text{UH}_{\text{Nac}}$  (O);  $\Delta\text{UH}_{\text{NS},6\text{S}}$  ( $\sigma$ );  $\Delta\text{H}_{\text{NS}}$  ( $\Delta$ );  $\Delta\text{UH}_{\text{NH}_2,16\text{S}}$  (+)  $\Delta\text{U}_{2\text{S}}\text{H}_{\text{NS}}$  (+, no activity).

**Figure 9** depicts the tandem use of heparinases and  $\Delta 4, 5$  glycuronidase in HSGAG compositional analyses. 200  $\mu\text{g}$  heparin was exhaustively digested with heparinases I, II, and III, after which  $\Delta 4, 5$  was added for a varying length of time. disaccharide products were resolved by capillary electrophoresis. Assignment of saccharide composition shown for each peak was confirmed by MALDI-MS. A., minus

-9-

$\Delta$ 4, 5 enzyme control; dashed line, B., minute (partial)  $\Delta$ 4, 5 incubation; C., 30 minute (exhaustive)  $\Delta$ 4, 5 incubation.

### **DETAILED DESCRIPTION OF THE INVENTION**

The invention in some aspects relates to  $\Delta$ 4, 5 glycuronidase, substantially pure  
5 forms thereof and uses thereof. In particular the invention arose, in part, from the cloning  
of  $\Delta$ 4, 5 glycuronidase that now enables one of skill in the art to produce the enzyme in  
large quantities and in substantially pure form. The invention also provides another tool  
that may be used to determine the structure of glycosaminoglycans and to help elucidate  
their role in cellular processes. It has now also been discovered that substantially pure  
10 preparations of  $\Delta$ 4, 5 glycuronidase having higher specific activity than the enzyme  
produced from culture may be produced. The invention also provides for cleavage of  
glycosaminoglycans (GAGs) as well as for the analysis of a sample of GAGs and for their  
sequencing. This present invention also provides treatment and prevention methods for  
cancer through the control of cellular proliferation, angiogenesis and /or coagulation  
15 disorders with the enzyme and/or its cleavage products (GAG fragments).

One aspect of the invention enables one of ordinary skill in the art, in light of the  
present disclosure, to produce substantially pure preparations of the  $\Delta$ 4, 5 glycuronidase  
by standard technology, including recombinant technology, direct synthesis,  
mutagenesis, etc. For instance, using recombinant technology one may produce  
20 substantially pure preparations of the  $\Delta$ 4, 5 glycuronidase having the amino acid  
sequences of SEQ ID NO:1 or encoded by the nucleic acid sequence of SEQ ID NO:2.  
In other aspects of the invention substantially pure preparations of the  $\Delta$ 4, 5  
glycuronidase having the amino acid sequences of SEQ ID NO:3 or encoded by the  
nucleic acid sequence of SEQ ID NO:4 can be prepared. One of skill in the art may also  
25 substitute appropriate codons to produce the desired amino acid substitutions in SEQ ID  
NOs:1 or 3 by standard site-directed mutagenesis techniques. One may also use any  
sequence which differs from the nucleic acid equivalents of SEQ ID NO:1 or 3 only due  
to the degeneracy of the genetic code as the starting point for site directed mutagenesis.  
The mutated nucleic acid sequence may then be ligated into an appropriate expression  
30 vector and expressed in a host such as *E. coli*. The resultant  $\Delta$ 4, 5 glycuronidase may  
then be purified by techniques, including those disclosed below.

-10-

As used herein, the term “substantially pure” means that the proteins are essentially free of other substances to an extent practical and appropriate for their intended use. In particular, the proteins are sufficiently pure and are sufficiently free from other biological constituents of their hosts cells so as to be useful in, for example, protein sequencing, or producing pharmaceutical preparations.

As used herein, a “substantially pure  $\Delta 4,5$  unsaturated glycuronidase” is a preparation of  $\Delta 4,5$  unsaturated glycuronidase which has been isolated or synthesized and which is greater than about 90% free of contaminants. A contaminant is a substance with which the  $\Delta 4,5$  unsaturated glycuronidase is ordinarily associated in nature that interfere with the activity of the enzyme. Preferably, the material is greater than about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or even greater than about 99% free of contaminants. The degree of purity may be assessed by means known in the art. One method for assessing the purity of the material may be accomplished through the use of specific activity assays. The native  $\Delta 4,5$  glycuronidase which has been described in the prior art as being isolated from *F. heparinum* has low specific activity because of impurities inherent in harvesting the enzyme from bacterial cultures of *F. heparinum*.

The invention also provides isolated polypeptides (including whole proteins and partial proteins), of  $\Delta 4, 5$  glycuronidase having the amino acid sequence of SEQ ID NO:1 and functional variants thereof. Isolated polypeptides are also provided by the invention that have the amino acid sequence of SEQ ID NO:3. Polypeptides can be isolated from biological samples, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Polypeptides can also be synthesized chemically using well-established methods of peptide synthesis.

As used herein with respect to polypeptides, “isolated” means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure. Because an isolated polypeptide may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the polypeptide may comprise only a small percentage by

-11-

weight of the preparation. The polypeptide is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e., isolated from other proteins.

Thus the term “ $\Delta$ 4, 5 glucuronidase polypeptides” embraces variants as well as the naturally occurring  $\Delta$ 4, 5 glucuronidase polypeptides. As used herein, a “variant” of a  $\Delta$ 4, 5 glucuronidase polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a native  $\Delta$ 4, 5 glucuronidase polypeptide. Variants include modified  $\Delta$ 4, 5 glucuronidase polypeptides that do not have altered function relative to the polypeptide of the unmodified (naturally occurring) sequence. Variants also include  $\Delta$ 4, 5 glucuronidase polypeptides with altered function. Modifications which create a  $\Delta$ 4, 5 glucuronidase polypeptide variant are typically made to the nucleic acid which encodes the  $\Delta$ 4, 5 glucuronidase polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and addition of amino acids or non-amino acid moieties to: 1) enhance a property of a  $\Delta$ 4, 5 glucuronidase polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 2) provide a novel activity or property to a  $\Delta$ 4, 5 glucuronidase polypeptide, such as addition of a detectable moiety; or 3) to provide equivalent or better interaction with other molecules (e.g., heparin). Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the  $\Delta$ 4, 5 glucuronidase amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus “design” a variant  $\Delta$ 4, 5 glucuronidase polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in Science 278:82-87, 1997, whereby proteins can be designed de novo. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

Variants can include  $\Delta$ 4, 5 glucuronidase polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted

-12-

disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a  $\Delta 4, 5$  glucuronidase polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

5           Mutations of a nucleic acid which encodes a  $\Delta 4, 5$  glucuronidase polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

10           Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant  $\Delta 4, 5$  glucuronidase polypeptides) which are  
15           silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a  $\Delta 4, 5$  glucuronidase gene or cDNA clone to enhance expression of the polypeptide.

20           One type of amino acid substitution is referred to as a "conservative substitution." As used herein, a "conservative amino acid substitution" or "conservative substitution" refers to an amino acid substitution in which the substituted amino acid residue is of similar charge as the replaced residue and is of similar or smaller size than the replaced residue. Conservative substitutions of amino acids include substitutions made amongst  
25           amino acids within the following groups: (a) the small non-polar amino acids, A, M, I, L, and V; (b) the small polar amino acids, G, S, T and C; (c) the amido amino acids, Q and N; (d) the aromatic amino acids, F, Y and W; (e) the basic amino acids, K, R and H; and (f) the acidic amino acids, E and D. Substitutions which are charge neutral and which replace a residue with a smaller residue may also be considered "conservative  
30           substitutions" even if the residues are in different groups (e.g., replacement of phenylalanine with the smaller isoleucine). The term "conservative amino acid substitution" also refers to the use of amino acid analogs or variants.

-13-

Methods for making amino acid substitutions, additions or deletions are well known in the art. The terms "conservative substitution", "non-conservative substitutions", "non-polar amino acids", "polar amino acids", and "acidic amino acids" are all used consistently with the prior art terminology. Each of these terms is well-known in the art and has been extensively described in numerous publications, including standard biochemistry text books, such as "Biochemistry" by Geoffrey Zubay, Addison-Wesley Publishing Co., 1986 edition, which describes conservative and non-conservative substitutions, and properties of amino acids which lead to their definition as polar, non-polar or acidic.

One skilled in the art will be able to predict the effect of a substitution by using routine screening assays, preferably the biological assays described herein. Modifications of peptide properties including thermal stability, enzymatic activity, hydrophobicity, susceptibility to proteolytic degradation or the tendency to aggregate with carriers or into multimers are assayed by methods well known to the ordinarily skilled artisan. For additional detailed description of protein chemistry and structure, see Schulz, G. E. et al., Principles of Protein Structure, Springer-Verlag, New York, 1979, and Creighton, T. E., Proteins: Structure and Molecular Principles, W. H. Freeman & Co., San Francisco, 1984.

Additionally, some of the amino acid substitutions are non-conservative substitutions. In certain embodiments where the substitution is remote from the active or binding sites, the non-conservative substitutions are easily tolerated provided that they preserve a tertiary structure characteristic of, or similar to, native  $\Delta 4, 5$  glycuronidase, thereby preserving the active and binding sites. Non-conservative substitutions, such as between, rather than within, the above groups (or two other amino acid groups not shown above), which will differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

In another set of embodiments an isolated nucleic acid equivalent of SEQ ID NO:2 encode the substantially pure  $\Delta 4, 5$  glycuronidase of the invention and functional variants thereof. In still further embodiments isolated nucleic acid equivalents of SEQ ID NO:4 are also given. According to the invention, isolated nucleic acid molecules that code for a  $\Delta 4, 5$  glycuronidase polypeptide are provided and include: (a) nucleic acid

-14-

molecules which hybridize under stringent conditions to a molecule selected from a group consisting of the nucleic acid equivalent of SEQ ID NO:2 or 4 and which code for a  $\Delta 4, 5$  glycuronidase polypeptide or parts thereof, (b) deletions, additions and substitutions of (a) which code for a respective  $\Delta 4, 5$  glycuronidase polypeptide or parts thereof, (c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and (d) complements of (a), (b) or (c).

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating  $\Delta 4, 5$  glycuronidase polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such



-15-

a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art.

One embodiment of the invention provides  $\Delta 4, 5$  glycuronidase that is recombinantly produced. Such molecules may be recombinantly produced using a vector including a coding sequence operably joined to one or more regulatory sequences. As used herein, a coding sequence and regulatory sequences are said to be “operably joined” when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein the coding sequences are operably joined to regulatory sequences. Two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Promoters may be constitutive or inducible. Regulatory sequences may also include enhancer sequences or upstream activator sequences, as desired.

As used herein, a “vector” may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids and phagemids. A cloning vector is one which is able to

-16-

replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired  
5 sequence may occur many times as the plasmid increases in copy number within the host bacterium, or just a single time per host as the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory  
10 sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are  
15 detectable by standard assays known in the art (e.g.,  $\beta$ -galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques. Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

20 As used herein, the term "stringent conditions" refers to parameters known to those skilled in the art. One example of stringent conditions is hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% bovine serum albumin (BSA), 25mM NaH<sub>2</sub>PO<sub>4</sub> (pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecylsulphate; and  
25 EDTA is ethylene diamine tetra acetic acid. There are other conditions, reagents, and so forth which can be used, which result in the same degree of stringency. A skilled artisan will be familiar with such conditions, and thus they are not given here.

The skilled artisan also is familiar with the methodology for screening cells for expression of such molecules, which then are routinely isolated, followed by isolation of  
30 the pertinent nucleic acid. Thus, homologs and alleles of the substantially pure  $\Delta 4$ , 5 glycuronidase of the invention, as well as nucleic acids encoding the same, may be obtained routinely, and the invention is not intended to be limited to the specific sequences disclosed. It will be understood that the skilled artisan will be able to

-17-

manipulate the conditions in a manner to permit the clear identification of homologs and alleles of the  $\Delta 4, 5$  glucuronidase nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent  
5 nucleic acid molecule and sequencing.

In general homologs and alleles typically will share at least about 40% nucleotide identity and/or at least about 50% amino acid identity with the equivalents of SEQ ID Nos: 2 and 1, respectively. Homologs and alleles of the invention are also intended to encompass the nucleic acid and amino acid equivalents of SEQ ID Nos: 4 and 3,  
10 respectively. In some instances sequences will share at least about 50% nucleotide identity and/or at least about 65% amino acid identity and in still other instances sequences will share at least about 60% nucleotide identity and/or at least about 75% amino acid identity. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through  
15 the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available at <http://www.ncbi.nlm.nih.gov>. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVêtor sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also are embraced by the  
20 invention.

In screening for  $\Delta 4, 5$  glucuronidase related genes, such as homologs and alleles of  $\Delta 4, 5$  glucuronidase, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film or a  
25 phosphorimager plate to detect the radioactive signal.

For prokaryotic systems, plasmid vectors that contain replication sites and control sequences derived from a species compatible with the host may be used. Examples of suitable plasmid vectors include pBR322, pUC18, pUC19 and the like; suitable phage or bacteriophage vectors include  $\lambda$ gt10,  $\lambda$ gt11 and the like; and suitable virus vectors  
30 include pMAM-neo, pKRC and the like. Preferably, the selected vector of the present invention has the capacity to autonomously replicate in the selected host cell. Useful

-18-

prokaryotic hosts include bacteria such as *E. coli*, *Flavobacterium heparinum*, *Bacillus*, *Streptomyces*, *Pseudomonas*, *Salmonella*, *Serratia*, and the like.

To express the substantially pure  $\Delta 4, 5$  glycuronidase of the invention in a prokaryotic cell, it is desirable to operably join the nucleic acid sequence of a substantially pure  $\Delta 4, 5$  glycuronidase of the invention to a functional prokaryotic promoter. Such promoter may be either constitutive or, more preferably, regulatable (i.e., inducible or derepressible). Examples of constitutive promoters include the *int* promoter of bacteriophage  $\lambda$ , the *bla* promoter of the  $\beta$ -lactamase gene sequence of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene sequence of pPR325, and the like. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage  $\lambda$  ( $P_L$  and  $P_R$ ), the *trp*, *recA*, *lacZ*, *lacI*, and *gal* promoters of *E. coli*, the  $\alpha$ -amylase (Ulmanen et al., *J. Bacteriol.* 162:176-182 (1985)) and the  $\zeta$ -28-specific promoters of *B. subtilis* (Gilman et al., *Gene sequence* 32:11-20 (1984)); the promoters of the bacteriophages of *Bacillus* (Gryczan, In: *The Molecular Biology of the Bacilli*, Academic Press, Inc., NY (1982)), and *Streptomyces* promoters (Ward et al., *Mol. Gen. Genet.* 203:468-478 (1986)).

Prokaryotic promoters are reviewed by Glick (*J. Ind. Microbiol.* 1:277-282 (1987)); Cenatiempo (*Biochimie* 68:505-516 (1986)); and Gottesman (*Ann. Rev. Genet.* 18:415-442 (1984)).

Proper expression in a prokaryotic cell also requires the presence of a ribosome binding site upstream of the encoding sequence. Such ribosome binding sites are disclosed, for example, by Gold et al. (*Ann. Rev. Microbiol.* 35:365-404 (1981)).

Because prokaryotic cells may not produce the  $\Delta 4, 5$  glycuronidase of the invention with normal eukaryotic glycosylation, expression of the  $\Delta 4, 5$  glycuronidase of the invention of the eukaryotic hosts is useful when glycosylation is desired. Preferred eukaryotic hosts include, for example, yeast, fungi, insect cells, and mammalian cells, either *in vivo* or in tissue culture. Mammalian cells which may be useful as hosts include HeLa cells, cells of fibroblast origin such as VERO or CHO-K1, or cells of lymphoid origin, such as the hybridoma SP2/0-AG14 or the myeloma P3x63Sg8, and their derivatives. Preferred mammalian host cells include SP2/0 and J558L, as well as neuroblastoma cell lines such as IMR 332 that may provide better capacities for correct

-19-

post-translational processing. Embryonic cells and mature cells of a transplantable organ also are useful according to some aspects of the invention.

In addition, plant cells are also available as hosts, and control sequences compatible with plant cells are available, such as the nopaline synthase promoter and  
5 polyadenylation signal sequences.

Another preferred host is an insect cell, for example in *Drosophila* larvae. Using insect cells as hosts, the *Drosophila* alcohol dehydrogenase promoter can be used (Rubin, *Science* 240:1453-1459 (1988)). Alternatively, baculovirus vectors can be engineered to express large amounts of the  $\Delta 4$ , 5 glycuronidase of the invention in insect  
10 cells (Jasny, *Science* 238:1653 (1987); Miller et al., In: *Genetic Engineering* (1986), Setlow, J.K., et al., eds., Plenum, Vol. 8, pp. 277-297).

Any of a series of yeast gene sequence expression systems which incorporate promoter and termination elements from the genes coding for glycolytic enzymes and which are produced in large quantities when the yeast are grown in media rich in glucose  
15 may also be utilized. Known glycolytic gene sequences can also provide very efficient transcriptional control signals. Yeast provide substantial advantages in that they can also carry out post-translational peptide modifications. A number of recombinant DNA strategies exist which utilize strong promoter sequences and high copy number plasmids which can be utilized for production of the desired proteins in yeast. Yeast recognize  
20 leader sequences on cloned mammalian gene sequence products and secrete peptides bearing leader sequences (i.e., pre-peptides).

A wide variety of transcriptional and translational regulatory sequences may be employed, depending upon the nature of the host. The transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine  
25 papilloma virus, simian virus, or the like, where the regulatory signals are associated with a particular gene sequence which has a high level of expression. Alternatively, promoters from mammalian expression products, such as actin, collagen, myosin, and the like, may be employed. Transcriptional initiation regulatory signals may be selected which allow for repression or activation, so that expression of the gene sequences can be  
30 modulated. Of interest are regulatory signals that are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or which are subject to chemical (such as metabolite) regulation.

-20-

As discussed above, expression of the  $\Delta 4$ , 5 glucuronidase of the invention in eukaryotic hosts is accomplished using eukaryotic regulatory regions. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis. Preferred eukaryotic promoters include, for example, the promoter of the mouse  
5 metallothionein I gene sequence (Hamer et al., *J. Mol. Appl. Gen.* 1:273-288 (1982)); the TK promoter of Herpes virus (McKnight, *Cell* 31:355-365 (1982)); the SV40 early promoter (Benoist et al., *Nature (London)* 290:304-310 (1981)); the yeast *gal4* gene sequence promoter (Johnston et al., *Proc. Natl. Acad. Sci. (USA)* 79:6971-6975 (1982); Silver et al., *Proc. Natl. Acad. Sci. (USA)* 81:5951-5955 (1984)).

10 As is widely known, translation of eukaryotic mRNA is initiated at the codon which encodes the first methionine. For this reason, it is preferable to ensure that the linkage between a eukaryotic promoter and a DNA sequence which encodes the  $\Delta 4$ , 5 glucuronidase of the invention does not contain any intervening codons which are capable of encoding a methionine (i.e., AUG). The presence of such codons results  
15 either in the formation of a fusion protein (if the AUG codon is in the same reading frame as the  $\Delta 4$ , 5 glucuronidase of the invention coding sequence) or a frame-shift mutation (if the AUG codon is not in the same reading frame as the  $\Delta 4$ , 5 glucuronidase of the invention coding sequence).

In one embodiment, a vector is employed which is capable of integrating the  
20 desired gene sequences into the host cell chromosome. Cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector. The marker may, for example, provide for prototrophy to an auxotrophic host or may confer biocide resistance to, e.g., antibiotics, heavy metals, or  
25 the like. The selectable marker gene sequence can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection. Additional elements may also be needed for optimal synthesis of the  $\Delta 4$ , 5 glucuronidase mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals. cDNA expression vectors incorporating such  
30 elements include those described by Okayama, *Molec. Cell. Biol.* 3:280 (1983).

In a preferred embodiment, the introduced sequence will be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a

-21-

wide variety of vectors may be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species. Preferred prokaryotic vectors include plasmids such as those capable of replication in *E. coli* (such as, for example, pBR322, ColEI, pSC101, pACYC 184, and  $\pi$ VX). Such plasmids are, for example, disclosed by Sambrook, et al. (5 *Molecular Cloning: A Laboratory Manual*, second edition, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory, 1989)). *Bacillus* plasmids include pC194, pC221, pT127, and the like. Such plasmids are disclosed by Gryczan (In: *The Molecular Biology of the Bacilli*, Academic Press, NY (1982), pp. 307-329). Suitable *Streptomyces* plasmids include pIJ101 (Kendall et al., *J. Bacteriol.* 169:4177-4183 (1987)), and streptomyces bacteriophages such as  $\phi$ C31 (Chater et al., In: *Sixth International Symposium on Actinomycetales Biology*, Akademiai Kiado, Budapest, Hungary (1986), 15 pp. 45-54). *Pseudomonas* plasmids are reviewed by John et al. (*Rev. Infect. Dis.* 8:693-704 (1986)), and Izaki (*Jpn. J. Bacteriol.* 33:729-742 (1978)).

Preferred eukaryotic plasmids include, for example, BPV, EBV, SV40, 2-micron circle, and the like, or their derivatives. Such plasmids are well known in the art (Botstein et al., *Miami Wntr. Symp.* 19:265-274 (1982); Broach, In: *The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 445-470 (1981); Broach, *Cell* 28:203-204 (1982); Bollon et al., *J. Clin. Hematol. Oncol.* 10:39-48 (1980); Maniatis, In: *Cell Biology: A Comprehensive Treatise*, Vol. 3, Gene Sequence Expression, Academic Press, NY, pp. 563-608 (1980)). Other preferred eukaryotic vectors are viral vectors. For example, and not by way of limitation, the pox virus, herpes virus, adenovirus and various retroviruses may be employed. The viral vectors may include either DNA or RNA viruses to cause expression of the insert DNA or insert RNA. 25

Once the vector or DNA sequence containing the construct(s) has been prepared for expression, the DNA construct(s) may be introduced into an appropriate host cell by any of a variety of suitable means, i.e., transformation, transfection, conjugation, protoplast fusion, electroporation, calcium phosphate-precipitation, direct microinjection, 30

-22-

and the like. Additionally, DNA or RNA encoding the  $\Delta 4, 5$  glycuronidase of the invention may be directly injected into cells or may be impelled through cell membranes after being adhered to microparticles. After the introduction of the vector, recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells.

- 5 Expression of the cloned gene sequence(s) results in the production of the  $\Delta 4, 5$  glycuronidase of the invention. This can take place in the transformed cells as such, or following the induction of these cells to differentiate (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like).

- The present invention also provides for the use of  $\Delta 4, 5$  glycuronidase as an enzymatic tool due to its substrate specificity and specific activity. In a direct and more rigorous comparison between the recombinant and native enzymes, it was found that at least some of the recombinant enzyme ( $\Delta 4, 5^{\Delta 20}$ ) possessed at least about two-fold higher and in some cases a roughly about three-fold higher specific activity relative to the native *Flavobacterial* enzyme when measured under identical reaction conditions.
- 10
- 15 Additionally, the activity of a cloned enzyme is not compromised by its recombinant expression in *E. coli*.

- The recombinant  $\Delta 4, 5$  glycuronidase exhibited a sharp ionic strength dependence. These results are interesting given both the ionic character of the disulfated heparin disaccharide used in the experiments described below as well as the many ionic residues present within the enzyme that may function in substrate binding and/or catalysis; many of these charged residues are conserved in structurally and functionally related enzymes.
- 20
- From a substrate perspective, all of the unsaturated disaccharides examined possess a negative charge (at pH 6.4) due to the C6 carboxylate of the uronic acid. It is possible that this acid acts as a critical structural determinant, especially given its proximity to the  $\Delta 4, 5$  bond. Charge neutralization of 6-O sulfate (e.g., in  $\Delta UH_{NS,6S}$ ) could possibly be another contributing factor. From the enzyme perspective, the recombinant glycuronidase ( $\Delta 4, 5^{\Delta 20}$ ) does possess 47 basic residues (theoretical pI of 8.5), including R151 whose position is invariantly conserved among the different glycuronidases examined. R151 may possibly interact with the uronic acid carboxylate. At the same
- 25
- 30 time,  $\Delta 4, 5$  also possesses 44 acidic residues. At least ten of these positions are highly conserved. Charge masking of some of these ionic residues (either acidic or basic) by increasing salt concentration might interfere with enzymatic activity. A similar



-23-

observation of this ionic strength dependency has been made for the heparinases [Ernst S, et al Expression in *Escherichia coli*, purification and characterization of heparinase I from *Flavobacterium heparinum*. *Biochem J.* 1996 Apr 15; 315 (pt 2): 589-97.]

A bell-shaped pH profile with a 6.4 optimum was also observed in the present  
5 invention. The 6.4 pH optimum generally agrees with results originally reported for the *F. heparinum*  $\Delta 4,5$  as well as for more recent results published for an unsaturated glucuronyl hydrolase purified from *Bacillus sp.* GL1 [Hashimoto, W., et al. (1999) *Arch Biochem Biophys* 368, 367-74]. This result logically implicates one or more histidine residues functioning in catalysis. While there are 11 histidines present within the  
10 primary sequence, three histidines (H115, H201, and H218) appear to be highly conserved. Interestingly, catalytically critical histidines also exist in all three heparin lyases [Pojasek, K., Shriver, Z., Hu, Y., and Sasisekharan, R. (2000) *Biochemistry* 39, 4012-9] as well as chondroitin AC lyase [Huang, W., Boju, L., Tkalec, L., Su, H., Yang, H. O., Gunay, N. S., Linhardt, R. J., Kim, Y. S., Matte, A., and Cygler, M. (2001)  
15 *Biochemistry* 40, 2359-72] from *Flavobacterium heparinum*. While these two classes of enzymes cleave glycosaminoglycans by somewhat different mechanisms (i.e.,  $\beta$ -elimination vs. hydrolysis), both would presumably involve acid-base catalysis, viz the imidazole.

The question of substrate specificity has now been considered from three  
20 structural perspectives: (1) the nature of the glycosidic linkage; (2) the relative sulfation pattern of the unsaturated disaccharide; and (3) the role of saccharide chain length (e.g., di- vs. tetrasaccharide). Our results indicate that for the recombinant  $\Delta 4,5$  glycuronidase, there is an unambiguous preference for the 1 $\rightarrow$ 4 linkage over the 1 $\rightarrow$ 3 linkage making heparin rather than chondroitin/dermatan and/or hyaluronan the best substrate. It should  
25 be noted, however, that while this linkage position is important, it is not absolute. Both chondroitin and hyaluronan  $\Delta 4,5$  disaccharides were hydrolyzed, albeit at much slower rates and using higher enzyme concentrations than were required to hydrolyze heparin disaccharides.

We also present a kinetic pattern of the  $\Delta 4,5$  glycuronidase with regard to the  
30 specific sulfation within a heparin disaccharide. First and foremost, we find that unsaturated saccharides containing a 2-O-sulfated uronidate ( $\Delta U_{2S}$ ) at the non-reducing end are in general not cleaved by the  $\Delta 4,5$  glycuronidase. Furthermore, the inability of a

-24-

2-O-sulfated disaccharide to competitively inhibit the hydrolysis of non 2-O-containing disaccharide substrates (such as  $\Delta\text{UH}_{\text{NAc}}$ ) further suggests that the presence of a 2-O sulfate precludes binding of this saccharide to the enzyme.

In considering the effect of specific sulfate groups present on the glucosamine, the enzyme may be loosely summarized as having a graded preference for 6-O-sulfation but a clear selection against unsubstituted or sulfated amines. This hierarchy is not an absolute distinction given the fact that all the non 2-O-containing heparin disaccharides examined were cleaved by the enzyme. Instead, it is based on relative kinetic parameters. This apparent substrate discrimination at the N and 6 positions of the glucosamine appears to be somewhat contextual, especially in the case of 6-O-sulfation. That is, while 6-O sulfation may bestow a favorable selectivity to a saccharide substrate, this positive effect may be offset by the presence of a deacetylated amine (e.g.,  $\Delta\text{UH}_{\text{NAc6S}}$  vs.  $\Delta\text{UH}_{\text{NH26S}}$  or  $\Delta\text{UH}_{\text{NS,6S}}$ ).

The structural preference the  $\Delta 4,5$  demonstrates against 2-O-sulfated uronidates along with a so-called "N-position" discrimination for the glucosamine may be exploited for use of the glycuronidase as an analytical tool for the compositional analyses of glycosaminoglycans. We were able to predict the extent and relative rates by which specific disaccharide "peaks" would disappear (i.e., due to the glycuronidase-dependent loss of absorbance at 232 nm.), based entirely on our kinetically defined substrate specificity determinations described in the Examples below. All 2-O-sulfate containing disaccharides tested were refractory to hydrolysis by the  $\Delta 4,5$  glycuronidase. On the other hand, the remaining disaccharides were hydrolyzed in a time-dependent fashion that corresponded to their relative substrate specificities (i.e.,  $\Delta\text{UH}_{\text{NAc6S}} > \Delta\text{UH}_{\text{NS,6S}} > \Delta\text{UH}_{\text{NS}}$ ).

From this experiment, another important and surprising observation was made, namely that the  $\Delta 4,5$  glycuronidase also hydrolyzes  $\Delta 4,5$  unsaturated tetrasaccharides. It is also very interesting to note that this particular tetrasaccharide is as good of a substrate as the disaccharide  $\Delta\text{UH}_{\text{NS}}$ . This observation may argue against a substrate discrimination used by the enzyme that is negatively based on increasing molecular weight as was first reported [Hovingh, P. and Linker, A. (1977) *Biochem J* 165, 287-93].

Therefore, the invention also provides for the cleavage of glycosaminoglycans using the substantially pure  $\Delta 4,5$  glycuronidase described herein. The  $\Delta 4,5$  glycuronidase

-25-

of the invention may be used to specifically cleave an HSGAG by contacting the HSGAG substrate with the  $\Delta 4,5$  glycuronidase of the invention. The invention is useful in a variety of *in vitro*, *in vivo* and *ex vivo* methods in which it is useful to cleave HSGAGs.

5           As used herein the terms "HSGAG", "GAG", and "glycosaminoglycans" are used interchangeably to refer to a family of molecules having heparin-like/heparan sulfate-like structures and properties. These molecules include but are not limited to low molecular weight heparin (LMWH), heparin, biotechnologically prepared heparin, chemically modified heparin, synthetic heparin, and heparan sulfate. The term  
10       "biotechnological heparin" encompasses heparin that is prepared from natural sources of polysaccharides which have been chemically modified and is described for example in Razi et al., Bioche. J. 1995 Jul 15;309 (Pt 2): 465-72. Chemically modified heparin is described in Yates et al., Carbohydrate Res (1996) Nov 20;294:15-27, and is known to those of skill in the art. Synthetic heparin is well known to those of skill in the art and is  
15       described in Petitou, M. et al., Bioorg Med Chem Lett. (1999) Apr 19;9(8):1161-6.

          Analysis of a sample of glycosaminoglycans is also possible with  $\Delta 4,5$  glycuronidase alone or in conjunction with other enzymes. Other HSGAG degrading enzymes include but are not limited to heparinase-I, heparinase- II , heparinase-III, heparinase-IV, D-glucuronidase and L-iduronidase, modified versions of heparinases,  
20       variants and functionally active fragments thereof.

          The methods that may be used to test the specific activity of  $\Delta 4,5$  glycuronidase of the present invention are known in the art, e.g., those described in the Examples. These methods may also be used to assess the function of variants and functionally active fragments of  $\Delta 4,5$  glycuronidase. The  $k_{cat}$  value may be determined using any  
25       enzymatic activity assay to assess the activity of a  $\Delta 4,5$  glycuronidase enzyme. Several such assays are well-known in the art. For instance, an assay for measuring  $k_{cat}$  is described in (Ernst, S. E., Venkataraman, G., Winkler, S., Godavarti, R., Langer, R., Cooney, C. and Sasisekharan. R. (1996) Biochem. J. 315, 589-597. The "native  $\Delta 4,5$  glycuronidase  $k_{cat}$  value" is the measure of enzymatic activity of the native  $\Delta 4,5$   
30       glycuronidase obtained from cell lysates of *F. heparinum* also described in the Examples below. Therefore, based on the disclosure provided herein, those of ordinary skill in the art will be able to identify other  $\Delta 4,5$  glycuronidase molecules having altered enzymatic

-26-

activity with respect to the native  $\Delta 4,5$  glycuronidase molecule such as functional variants.

The term "specific activity" as used herein refers to the enzymatic activity of a preparation of  $\Delta 4,5$  glycuronidase. In general, it is preferred that the substantially pure and/or isolated  $\Delta 4,5$  glycuronidase preparations of the invention have a specific activity of at least about 60 picomoles of substrate hydrolyzed per minute per picomole of enzyme. This generally corresponds to a  $k_{cat}$  of at least about 10 per second for the enzyme using a substrate such as heparin disaccharide  $\Delta UH_{NAC}$ .

Due to the activity of  $\Delta 4,5$  glycuronidase on glycosaminoglycans, the product profile produced by a  $\Delta 4,5$  glycuronidase may be determined by any method known in the art for examining the type or quantity of degradation product produced by  $\Delta 4,5$  glycuronidase alone or in combination with other enzymes. One of skill in the art will also recognize that the  $\Delta 4,5$  glycuronidase may also be used to assess the purity of glycosaminoglycans in a sample. One preferred method for determining the type and quantity of product is described in Rhomberg, A.J. et al., *PNAS*, v. 95, p. 4176-4181, (April 1998), which is hereby incorporated in its entirety by reference. The method disclosed in the Rhomberg reference utilizes a combination of mass spectrometry and capillary electrophoretic techniques to identify the enzymatic products produced by heparinase. The Rhomberg study utilizes heparinase to degrade HSGAGs to produce HSGAG oligosaccharides. MALDI (Matrix-Assisted Laser Desorption Ionization) mass spectrometry can be used for the identification and semiquantitative measurement of substrates, enzymes, and end products in the enzymatic reaction. The capillary electrophoresis technique separates the products to resolve even small differences amongst the products and is applied in combination with mass spectrometry to quantitate the products produced. Capillary electrophoresis may even resolve the difference between a disaccharide and its semicarbazone derivative. Detailed methods for sequencing polysaccharides and other polymers are disclosed in co-pending U.S. Patent Applications Serial Nos. 09/557,997 and 09/558,137, both filed on April 24, 2000 and having common inventorship. The entire contents of both applications are hereby incorporated by reference.

Briefly, the method is performed by enzymatic digestion, followed by mass spectrometry and capillary electrophoresis. The enzymatic assays can be performed in a

-27-

variety of manners, as long as the assays are performed identically on the  $\Delta 4,5$  glycuronidase, so that the results may be compared. In the example described in the Rhomberg reference, enzymatic reactions are performed by adding 1 mL of enzyme solution to 5 mL of substrate solution. The digestion is then carried out at room temperature (22°C), and the reaction is stopped at various time points by removing 0.5 mL of the reaction mixture and adding it to 4.5 mL of a MALDI matrix solution, such as caffeic acid (approximately 12 mg/mL) and 70% acetonitrile/water. The reaction mixture is then subjected to MALDI mass spectrometry. The MALDI surface is prepared by the method of Xiang and Beavis (Xiang and Beavis (1994) *Rapid. Commun. Mass. Spectrom.* 8, 199-204). A two-fold lower access of basic peptide (Arg/Gly)<sub>15</sub> is premixed with matrix before being added to the oligosaccharide solution. A 1 mL aliquot of sample/matrix mixture containing 1-3 picomoles of oligosaccharide is deposited on the surface. After crystallization occurs (typically within 60 seconds), excess liquid is rinsed off with water. MALDI mass spectrometry spectra is then acquired in the linear mode by using a PerSeptive Biosystems (Framingham, MA) Voyager Elite reflectron time-of-flight instrument fitted with a 337 nanometer nitrogen laser. Delayed extraction is used to increase resolution (22 kV, grid at 93%, guidewire at 0.15%, pulse delay 150 ns, low mass gate at 1,000, 128 shots averaged). Mass spectra are calibrated externally by using the signals for proteinated (Arg/Gly)<sub>15</sub> and its complex with the oligosaccharide.

Capillary electrophoresis may then be performed on a Hewlett-Packard<sup>3D</sup> CE unit by using uncoated fused silica capillaries (internal diameter 75 micrometers, outer diameter 363 micrometers,  $l_{\text{det}}$  72.1 cm, and  $l_{\text{tot}}$  85 cm). Analytes are monitored by using UV detection at 230 nm and an extended light path cell (Hewlett-Packard). The electrolyte is a solution of 10 mL dextran sulfate and 50 millimolar Tris/phosphoric acid (pH2.5). Dextran sulfate is used to suppress nonspecific interactions of the heparin oligosaccharides with a silica wall. Separations are carried out at 30 kV with the anode at the detector side (reversed polarity). A mixture of a 1/5-naphtalenedisulfonic acid and 2-naphtalenesulfonic acid (10 micromolar each) is used as an internal standard.

Other methods for assessing the product profile may also be utilized. For instance, other methods include methods which rely on parameters such as viscosity (Jandik, K.A., Gu, K. and Linhardt, R.J., (1994), *Glycobiology*, 4:284-296) or total UV

-28-

absorbance (Ernst, S. et al., (1996), *Biochem. J.*, 315:589-597) or mass spectrometry or capillary electrophoresis alone.

The  $\Delta 4,5$  glycuronidase molecules of the invention are also useful as tools for sequencing HSGAGs. Detailed methods for sequencing polysaccharides and other polymers are disclosed in co-pending U.S. Patent Applications Serial Nos. 09/557,997 and 09/558,137, both filed on April 24, 2000 and having common inventorship. These methods utilize tools such as heparinases in the sequencing process. The  $\Delta 4,5$  glycuronidase of the invention is useful as such a tool.

One of ordinary skill in the art, in light of the present disclosure, is enabled to produce substantially pure preparations of HSGAG and/or GAG fragment compositions utilizing the  $\Delta 4, 5$  glycuronidase molecules alone or in conjunction with other enzymes. These GAG fragments have many therapeutic utilities. The glycuronidase molecules and/or GAG fragments can be used for the treatment of any type of condition in which GAG fragment therapy has been identified as a useful therapy, e.g., preventing coagulation, inhibiting angiogenesis, inhibiting proliferation. The GAG fragment preparations are prepared from HSGAG sources. A "HSGAG source" as used herein refers to heparin-like/heparan sulfate-like glycosaminoglycan composition which can be manipulated to produce GAG fragments using standard technology, including enzymatic degradation etc. As described above, HSGAGs include but are not limited to isolated heparin, chemically modified heparin, biotechnology prepared heparin, synthetic heparin, heparan sulfate, and LMWH. Thus HSGAGs can be isolated from natural sources, prepared by direct synthesis, mutagenesis, etc.

Thus, the methods of the invention enable one of skill in the art to prepare or identify an appropriate composition of GAG fragments, depending on the subject and the disorder being treated. These compositions of GAG fragments may be used alone or in combination with the  $\Delta 4,5$  glycuronidase and/or other enzymes. Likewise  $\Delta 4, 5$  glycuronidase and/or other enzymes may also be used to produce GAG fragments *in vivo*.

The compositions of the invention can be used for the treatment of any type of condition in which GAG fragment therapy has been identified as a useful therapy. Thus, the invention is useful in a variety of *in vitro*, *in vivo* and *ex vivo* methods in which therapies are useful. For instance, it is known that GAG fragments are useful for

-29-

preventing coagulation, inhibiting cancer cell growth and metastasis, preventing angiogenesis, preventing neovascularization, preventing psoriasis. The GAG fragment compositions may also be used in *in vitro* assays, such as a quality control sample.

Each of these disorders is well-known in the art and is described, for instance, in  
5 *Harrison's Principles of Internal Medicine* (McGraw Hill, Inc., New York), which is incorporated by reference.

In one embodiment the preparations of the invention are used for inhibiting angiogenesis. An effective amount for inhibiting angiogenesis of the GAG fragment preparation is administered to a subject in need of treatment thereof. Angiogenesis as  
10 used herein is the inappropriate formation of new blood vessels. "Angiogenesis" often occurs in tumors when endothelial cells secrete a group of growth factors that are mitogenic for endothelium causing the elongation and proliferation of endothelial cells which results in a generation of new blood vessels. Several of the angiogenic mitogens are heparin binding peptides which are related to endothelial cell growth factors. The  
15 inhibition of angiogenesis can cause tumor regression in animal models, suggesting a use as a therapeutic anticancer agent. An effective amount for inhibiting angiogenesis is an amount of GAG fragment preparation which is sufficient to diminish the number of blood vessels growing into a tumor. This amount can be assessed in an animal model of tumors and angiogenesis, many of which are known in the art.

20 The  $\Delta 4, 5$  glycuronidase is, in some embodiments, immobilized on a support. The glycuronidase may be immobilized to any type of support but if the support is to be used *in vivo* or *ex vivo* it is desired that the support is sterile and biocompatible. A biocompatible support is one which would not cause an immune or other type of damaging reaction when used in a subject. The  $\Delta 4, 5$  glycuronidase may be immobilized  
25 by any method known in the art. Many methods are known for immobilizing proteins to supports. A "solid support" as used herein refers to any solid material to which a polypeptide can be immobilized.

Solid supports, for example, include but are not limited to membranes, e.g., natural and modified celluloses such as nitrocellulose or nylon, Sepharose, Agarose,  
30 glass, polystyrene, polypropylene, polyethylene, dextran, amylases, polyacrylamides, polyvinylidene difluoride, other agaroses, and magnetite, including magnetic beads. The carrier can be totally insoluble or partially soluble and may have any possible structural

-30-

configuration. Thus, the support may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube or microplate well, or the external surface of a rod.

Alternatively, the surface may be flat such as a sheet, test strip, bottom surface of a microplate well, etc.

5           The  $\Delta 4, 5$  glycuronidase of the invention may also be used to remove active GAGs from a GAG containing fluid. A GAG containing fluid is contacted with the  $\Delta 4, 5$  glycuronidase of the invention to degrade the GAG. The method is particularly useful for the *ex vivo* removal of GAGs from blood. In one embodiment of the invention the  $\Delta 4, 5$  glycuronidase is immobilized on a solid support as is conventional in the art. The solid support containing the immobilized  $\Delta 4, 5$  glycuronidase may be used in  
10           extracorporeal medical devices (e.g. hemodialyzer, pump-oxygenator) for systemic heparinization to prevent the blood in the device from clotting. The support membrane containing immobilized  $\Delta 4, 5$  glycuronidase is positioned at the end of the device to neutralize the GAG before the blood is returned to the body.

15           Thus, the  $\Delta 4, 5$  glycuronidase molecules are useful for treating or preventing disorders associated with coagulation. A "disease associated with coagulation" as used herein refers to a condition characterized by an interruption in the blood supply to a tissue due to a blockage of the blood vessel responsible for supplying blood to the tissue such as is seen for myocardial or cerebral infarction. A cerebral ischemic attack or  
20           cerebral ischemia is a form of ischemic condition in which the blood supply to the brain is blocked. This interruption in the blood supply to the brain may result from a variety of causes, including an intrinsic blockage or occlusion of the blood vessel itself, a remotely originated source of occlusion, decreased perfusion pressure or increased blood viscosity resulting in inadequate cerebral blood flow, or a ruptured blood vessel in the  
25           subarachnoid space or intracerebral tissue.

          The  $\Delta 4, 5$  glycuronidase or the GAG fragments generated therewith may be used alone or in combination with a therapeutic agent for treating a disease associated with coagulation. Examples of therapeutics useful in the treatment of diseases associated with coagulation include anticoagulation agents, antiplatelet agents, and thrombolytic  
30           agents.

          Anticoagulation agents prevent the coagulation of blood components and thus prevent clot formation. Anticoagulants include, but are not limited to, heparin, warfarin,



-31-

coumadin, dicumarol, phenprocoumon, acenocoumarol, ethyl biscoumacetate, and indandione derivatives.

Antiplatelet agents inhibit platelet aggregation and are often used to prevent thromboembolic stroke in patients who have experienced a transient ischemic attack or stroke. Antiplatelet agents include, but are not limited to, aspirin, thienopyridine derivatives such as ticlopidine and clopidogrel, dipyridamole and sulfinpyrazone, as well as RGD mimetics and also antithrombin agents such as, but not limited to, hirudin.

Thrombolytic agents lyse clots which cause the thromboembolic stroke. Thrombolytic agents have been used in the treatment of acute venous thromboembolism and pulmonary emboli and are well known in the art (e.g. see Hennekens et al, *J Am Coll Cardiol*; v. 25 (7 supp), p. 18S-22S (1995); Holmes, et al, *J Am Coll Cardiol*; v.25 (7 suppl), p. 10S-17S(1995)). Thrombolytic agents include, but are not limited to, plasminogen, a<sub>2</sub>-antiplasmin, streptokinase, antistreplase, tissue plasminogen activator (tPA), and urokinase. "tPA" as used herein includes native tPA and recombinant tPA, as well as modified forms of tPA that retain the enzymatic or fibrinolytic activities of native tPA. The enzymatic activity of tPA can be measured by assessing the ability of the molecule to convert plasminogen to plasmin. The fibrinolytic activity of tPA may be determined by any *in vitro* clot lysis activity known in the art, such as the purified clot lysis assay described by Carlson, et. al., *Anal. Biochem.* 168, 428-435 (1988) and its modified form described by Bennett, W. F. et al., 1991, *J. Biol. Chem.* 266(8):5191-5201, the entire contents of which are hereby incorporated by reference.

The invention compositions of the invention are useful for the same purposes as heparinases and the degradation products of heparinases (HSGAG fragments). Thus, for instance, the compositions of the invention are useful for treating and preventing cancer cell proliferation and metastasis. Thus, according to another aspect of the invention, there is provided methods for treating subjects having or at risk of having cancer.

Critically, HSGAGs (along with collagen) are key components of the cell surface-extracellular matrix (ECM) interface. While collagen-like proteins provide the necessary extracellular scaffold for cells to attach and form tissues, the complex polysaccharides fill the space created by the scaffold and act as a molecular sponge by specifically binding and regulating the biological activities of numerous signaling molecules like growth factors, cytokines etc. It has recently been recognized that cells synthesize distinct HSGAG sequences and decorate themselves with these sequences,

-32-

using the extraordinary information content present in the sequences to bind specifically to many signaling molecules and thereby regulate various biological processes.

The invention also contemplates the use of therapeutic GAG fragments for the treatment and prevention of tumor cell proliferation and metastasis. A therapeutic GAG  
5 fragment as used herein refers to a molecule or molecules which are pieces or fragments of a GAG that have been identified through the use of the  $\Delta 4, 5$  glycuronidase possibly along with other native and/or modified heparinases.

The invention also encompasses screening assays for identifying therapeutic GAG fragments for the treatment of a tumor and for preventing metastasis. The assays  
10 are accomplished by treating a tumor or isolated tumor cells with  $\Delta 4, 5$  glycuronidase and/or other native or modified heparinases and isolating the resultant GAG fragments. Surprisingly, these GAG fragments have therapeutic activity in the prevention of tumor cell proliferation and metastasis. Thus the invention encompasses individualized therapies, in which a tumor or portion of a tumor is isolated from a subject and used to  
15 prepare the therapeutic GAG fragments. These therapeutic fragments can be re-administered to the subject to protect the subject from further tumor cell proliferation or metastasis or from the initiation of metastasis if the tumor is not yet metastatic. Alternatively the fragments can be used in a different subject having the same type or tumor or a different type of tumor.

20 The term "therapeutic GAG fragment" as used herein refers to a GAG which has therapeutic activity in that it prevents the proliferation and/or metastasis of a tumor cell. Such compounds may be generated using  $\Delta 4, 5$  glycuronidase to produce therapeutic fragments or they may be synthesized de novo. Putative GAG fragments can be tested for therapeutic activity using any of the assays described herein or known in the art.  
25 Thus the therapeutic GAG fragment may be a synthetic GAG fragment generated based on the sequence of the GAG fragment identified when the tumor is contacted with  $\Delta 4, 5$  glycuronidase, or having minor variations which do not interfere with the activity of the compound. Alternatively the therapeutic GAG fragment may be an isolated GAG fragment produced when the tumor is contacted with  $\Delta 4, 5$  glycuronidase.

30 The invention is useful for treating and/or preventing tumor cell proliferation or metastasis in a subject. The terms "treat" and "treating" tumor cell proliferation as used herein refer to inhibiting completely or partially the proliferation or metastasis of a

-33-

cancer or tumor cell, as well as inhibiting any increase in the proliferation or metastasis of a cancer or tumor cell.

A "subject having a cancer" is a subject that has detectable cancerous cells. The cancer may be a malignant or non-malignant cancer. Cancers or tumors include but are not limited to biliary tract cancer; brain cancer; breast cancer; cervical cancer; 5 choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; intraepithelial neoplasms; lymphomas; liver cancer; lung cancer (e.g. small cell and non-small cell); melanoma; neuroblastomas; oral cancer; ovarian cancer; pancreas cancer; prostate cancer; rectal cancer; sarcomas; skin cancer; testicular cancer; thyroid 10 cancer; and renal cancer, as well as other carcinomas and sarcomas.

A "subject at risk of having a cancer" as used herein is a subject who has a high probability of developing cancer. These subjects include, for instance, subjects having a genetic abnormality, the presence of which has been demonstrated to have a correlative relation to a higher likelihood of developing a cancer and subjects exposed to cancer 15 causing agents such as tobacco, asbestos, or other chemical toxins, or a subject who has previously been treated for cancer and is in apparent remission. When a subject at risk of developing a cancer is treated with a  $\Delta 4, 5$  glucuronidase or degradation product thereof the subject may be able to kill the cancer cells as they develop.

Effective amounts of the  $\Delta 4, 5$  glucuronidase, variant  $\Delta 4, 5$  glucuronidase or 20 therapeutic GAGs of the invention are administered to subjects in need of such treatment. Effective amounts are those amounts which will result in a desired improvement in the condition or symptoms of the condition, e.g., for cancer this is a reduction in cellular proliferation or metastasis, without causing other medically unacceptable side effects. Such amounts can be determined with no more than routine 25 experimentation. It is believed that doses ranging from 1 nanogram/kilogram to 100 milligrams/kilogram, depending upon the mode of administration, will be effective. The absolute amount will depend upon a variety of factors (including whether the administration is in conjunction with other methods of treatment, the number of doses and individual patient parameters including age, physical condition, size and weight) and 30 can be determined with routine experimentation. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical

judgment. The mode of administration may be any medically acceptable mode including oral, subcutaneous, intravenous, etc.

In some aspects of the invention the effective amount of  $\Delta 4, 5$  glycuronidase or therapeutic GAG is that amount effective to prevent invasion of a tumor cell across a barrier. The invasion and hmetastasis of cancer is a complex process which involves changes in cell adhesion properties which allow a transformed cell to invade and migrate through the extracellular matrix (ECM) and acquire anchorage-independent growth properties Liotta, L. A., et al., Cell 64:327-336, 1991. Some of these changes occur at focal adhesions, which are cell/ECM contact points containing membrane-associated, cytoskeletal, and intracellular signaling molecules. Metastatic disease occurs when the disseminated foci of tumor cells seed a tissue which supports their growth and propagation, and this secondary spread of tumor cells is responsible for the morbidity and mortality associated with the majority of cancers. Thus the term "metastasis" as used herein refers to the invasion and migration of tumor cells away from the primary tumor site.

The barrier for the tumor cells may be an artificial barrier *in vitro* or a natural barrier *in vivo*. *In vitro* barriers include but are not limited to extracellular matrix coated membranes, such as Matrigel. Thus the  $\Delta 4, 5$  glycuronidase compositions or degradation products thereof can be tested for their ability to inhibit tumor cell invasion in a Matrigel invasion assay system as described in detail by Parish, C.R., et al., "A Basement-Membrane Permeability Assay which Correlates with the Metastatic Potential of Tumour Cells," Int. J. Cancer, 1992, 52:378-383. Matrigel is a reconstituted basement membrane containing type IV collagen, laminin, heparan sulfate proteoglycans such as perlecan, which bind to and localize bFGF, vitronectin as well as transforming growth factor-  $\beta$  (TGF- $\beta$ ), urokinase-type plasminogen activator (uPA), tissue plasminogen activator (tPA), and the serpin known as plasminogen activator inhibitor type 1 (PAI-1). Other *in vitro* and *in vivo* assays for metastasis have been described in the prior art, see, e.g., US Patent No. 5,935,850, issued on August 10, 1999, which is incorporated by reference. An *in vivo* barrier refers to a cellular barrier present in the body of a subject.

In general, when administered for therapeutic purposes, the formulations of the invention are applied in pharmaceutically acceptable solutions. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents,

-35-

preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.

The compositions of the invention may be administered *per se* (neat) or in the form of a pharmaceutically acceptable salt. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, pharmaceutically acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.

Suitable buffering agents include: acetic acid and a salt (1-2% W/V); citric acid and a salt (1-3% W/V); boric acid and a salt (0.5-2.5% W/V); and phosphoric acid and a salt (0.8-2% W/V). Suitable preservatives include benzalkonium chloride (0.003-0.03% W/V); chlorobutanol (0.3-0.9% W/V); parabens (0.01-0.25% W/V) and thimerosal (0.004-0.02% W/V).

The present invention provides pharmaceutical compositions, for medical use, which comprise  $\Delta 4, 5$  glycuronidase, variant  $\Delta 4, 5$  glycuronidase of the invention, or therapeutic GAG fragments together with one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients. The term "pharmaceutically-acceptable carrier" as used herein, and described more fully below, means one or more compatible solid or liquid filler, dilutants or encapsulating substances which are suitable for administration to a human or other animal. In the present invention, the term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the  $\Delta 4, 5$  glycuronidase of the present invention or other compositions, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficiency.

-36-

A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular active agent selected, the particular condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of an immune response without causing clinically unacceptable adverse effects. A preferred mode of administration is a parenteral route. The term "parenteral" includes subcutaneous injections, intravenous, intramuscular, intraperitoneal, intra sternal injection or infusion techniques. Other modes of administration include oral, mucosal, rectal, vaginal, sublingual, intranasal, intratracheal, inhalation, ocular, transdermal, etc.

For oral administration, the compounds can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions or may be administered without any carriers.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as

-37-

glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid  
5 paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or  
10 lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon  
15 dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.* gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds, when it is desirable to deliver them systemically, may be  
20 formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing  
25 and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic  
30 fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may

-38-

also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

5           The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

10           In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

15           The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

20           Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as  
25           described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer, *Science* 249:1527-1533, 1990, which is incorporated herein by reference.

30           The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active  $\Delta 4, 5$  glucuronidase into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the polymer into association with a liquid carrier, a



-39-

finely divided solid carrier, or both, and then, if necessary, shaping the product. The polymer may be stored lyophilized.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the heparinases of the invention, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer based systems such as polylactic and polyglycolic acid, polyanhydrides and polycaprolactone; nonpolymer systems that are lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-, di and triglycerides; hydrogel release systems; silastic systems; peptide based systems; wax coatings, compressed tablets using conventional binders and excipients, partially fused implants and the like. Specific examples include, but are not limited to: (a) erosional systems in which the polysaccharide is contained in a form within a matrix, found in U.S. Patent Nos. 4,452,775 (Kent); 4,667,014 (Nestor et al.); and 4,748,034 and 5,239,660 (Leonard) and (b) diffusional systems in which an active component permeates at a controlled rate through a polymer, found in U.S. Patent Nos. 3,832,253 (Higuchi et al.) and 3,854,480 (Zaffaroni). In addition, a pump-based hardware delivery system can be used, some of which are adapted for implantation.

A subject is any human or non-human vertebrate, e.g., dog, cat, horse, cow, pig.

When administered to a patient undergoing cancer treatment, the  $\Delta 4$ , 5 glycuronidase or therapeutic GAG compounds may be administered in cocktails containing other anti-cancer agents. The compounds may also be administered in cocktails containing agents that treat the side-effects of radiation therapy, such as anti-emetics, radiation protectants, etc.

Anti-cancer drugs that can be co-administered with the compounds of the invention include, but are not limited to Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adriamycin; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropiramine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; Cisplatin;

Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine;  
 Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine;  
 Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin  
 Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate;  
 5 Duazomycin; Edatrexate; Eflornithine Hydrochloride; Elsamitrucin; Enloplatin;  
 Enpromate; Epirpropidine; Epirubicin Hydrochloride; Erbulozole; Esorubicin  
 Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Etoposide;  
 Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide;  
 Floxuridine; Fludarabine Phosphate; Fluorouracil; Flurocitabine; Fosquidone; Fostriecin  
 10 Sodium; Gemcitabine; Gemcitabine Hydrochloride; Hydroxyurea; Idarubicin  
 Hydrochloride; Ifosfamide; Ilmofofosine; Interferon Alfa-2a; Interferon Alfa-2b; Interferon  
 Alfa-n1; Interferon Alfa-n3; Interferon Beta- I a; Interferon Gamma- I b; Iproplatin;  
 Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole  
 Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride;  
 15 Masoprocol; Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate;  
 Melengestrol Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate;  
 Methotrexate Sodium; Metoprine; Meturedapa; Mitindomide; Mitocarcin; Mitocromin;  
 Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride;  
 Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel;  
 20 Pegaspargase; Peliomycin; Pentamustine; Peplomycin Sulfate; Perfosfamide;  
 Pipobroman; Piposulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer  
 Sodium; Porfiromycin; Prednimustine; Procarbazine Hydrochloride; Puromycin;  
 Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safingol; Safingol  
 Hydrochloride; Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin;  
 25 Spirogermanium Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin;  
 Sulofenur; Talisomycin; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride;  
 Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine; Thiotepa;  
 Tiazofurin; Tirapazamine; Topotecan Hydrochloride; Toremifene Citrate; Trestolone  
 Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Triptorelin;  
 30 Tubulozole Hydrochloride; Uracil Mustard; Uredapa; Vapreotide; Verteporfin;  
 Vinblastine Sulfate; Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine  
 Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine  
 Sulfate; Vinzolidine Sulfate; Vorozole; Zaniplatin; Zinostatin; Zorubicin Hydrochloride.

-41-

The  $\Delta 4, 5$  glycuronidase or therapeutic GAG compounds may also be linked to a targeting molecule. A targeting molecule is any molecule or compound which is specific for a particular cell or tissue and which can be used to direct the  $\Delta 4, 5$  glycuronidase or therapeutic GAG to the cell or tissue. Preferably the targeting molecule is a molecule  
5 which specifically interacts with a cancer cell or a tumor. For instance, the targeting molecule may be a protein or other type of molecule that recognizes and specifically interacts with a tumor antigen.

Tumor-antigens include Melan-A/M-ART-1, Dipeptidyl peptidase IV (DPPIV), adenosine deaminase-binding protein (ADAbp), cyclophilin b, Colorectal associated  
10 antigen (CRC)--C017-1A/GA733, Carcinoembryonic Antigen (CEA) and its immunogenic epitopes CAP-1 and CAP-2, etv6, aml1, Prostate Specific Antigen (PSA) and its immunogenic epitopes PSA-1, PSA-2, and PSA-3, prostate-specific membrane antigen (PSMA), T-cell receptor/CD3-zeta chain, MAGE-family of tumor antigens (e.g., MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7,  
15 MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, MAGE-Xp2 (MAGE-B2), MAGE-Xp3 (MAGE-B3), MAGE-Xp4 (MAGE-B4), MAGE-C1, MAGE-C2, MAGE-C3, MAGE-C4, MAGE-C5), GAGE-family of tumor antigens (e.g., GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, GAGE-9), BAGE, RAGE, LAGE-1, NAG, GnT-V, MUM-1, CDK4, tyrosinase, p53, MUC family,  
20 HER2/neu, p21ras, RCAS1,  $\alpha$ -fetoprotein, E-cadherin,  $\alpha$ -catenin,  $\beta$ -catenin and  $\gamma$ -catenin, p120ctn, gp100<sup>Pmel117</sup>, PRAME, NY-ESO-1, brain glycogen phosphorylase, SSX-1, SSX-2 (HOM-MEL-40), SSX-1, SSX-4, SSX-5, SCP-1, CT-7, cdc27, adenomatous polyposis coli protein (APC), fodrin, P1A, Connexin 37, Ig-idiotypic, p15, gp75, GM2 and GD2 gangliosides, viral products such as human papilloma virus  
25 proteins, Smad family of tumor antigens, lmp-1, EBV-encoded nuclear antigen (EBNA)-1, and c-erbB-2.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and  
30 co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

## EXAMPLES

### **Materials And Methods**

*Chemicals and reagents.* Unless otherwise stated, biochemicals were purchased from Sigma Aldrich Chemical (St. Louis, MO). Disaccharides were purchased from Calbiochem (San Diego, CA). Reagents for  $\lambda$ ZAP II genomic library construction and screening were obtained from Stratagene (La Jolla, CA). Restriction endonucleases were purchased from New England Biolabs (Beverly, MA). DNA oligonucleotide primers were manufactured by Invitrogen/Life Technologies (Carlsbad, CA). Additional molecular cloning reagents were obtained from the manufacturers listed.

*Bacterial strains and growth conditions.* *F. heparinum* (*Pedobacter heparinus*) was obtained as a lyophilized stock from American Type Culture Collection (ATCC, Manassas, VA), stock no. 13125. Rehydrated cultures were grown aerobically at 30°C with moderate shaking to an optical density ( $A_{600}$ ) between 1.5 and 2 in defined media containing 6.4 mM  $\text{NaH}_2\text{PO}_4$ , 7.6 mM  $\text{Na}_2\text{HPO}_4$ , 12 mM  $\text{KH}_2\text{PO}_4$ , 14.3 mM  $\text{K}_2\text{HPO}_4$ , 1.7 mM NaCl, and 1.9 mM  $\text{NH}_4\text{Cl}$ , pH 6.9 and supplemented with 0.1 mM trace metals  $\text{CaCl}_2$ ,  $\text{FeSO}_4$ ,  $\text{CuSO}_4$ ,  $\text{NaMoO}_4$ ,  $\text{CoCl}_2$ , and  $\text{MnSO}_4$  (added from a 100X stock in 10 mM  $\text{H}_2\text{SO}_4$ ), 0.8% glucose, 0.05% methionine, 0.05% histidine, 2 mM  $\text{MgSO}_4$ , and 0.1% heparin all added under sterile conditions. *E. coli* strains included TOP10 (Invitrogen) or DH5 $\alpha$  for PCR cloning and subcloning and BL21(DE3) (Novagen, Madison WI) for recombinant protein expression. Bacteriophage host strains XL1-Blue MRF' and SOLR were obtained from Stratagene.

*Purification of glycuronidase peptides and protein sequencing.* The 4, 5 glycuronidase was purified from 10 liter fermentation cultures using a method such as those described in McLean, M. W., Bruce, J. S., Long, W. F., and Williamson, F. B., 1984, *Eur J Biochem* 145, 607-15.

*Molecular cloning of the  $\Delta 4, 5$  glycuronidase gene from *F. heparinum* genomic DNA.*

*Flavobacterial* genomic DNA was isolated from 10 mL of *Flavobacterial* culture using the QIAGEN DNeasy DNA purification kit according to the Manufacturer's instructions for gram-negative bacteria using approximately  $2 \times 10^9$  cells per column. Following purification, genomic DNA was ethanol precipitated and resuspended in TE, pH 7.5 at 0.5 mg/mL. The quality of genomic DNA was confirmed

-43-

spectrophotometrically at 260/280 nm, by electrophoresis on a 0.5% agarose gel and by PCR using *Flavobacterium* specific primers.

The following degenerate primers were synthesized from peptides corresponding initially to peaks 19 and 24 (Example 1): 5'

- 5 GARACNCA YCARGGNYTNACNAA YGAR 3' (SEQ ID NO. 5) (peak 19 forward), 5' YTCRTTNGTNARNCCYTGR TGNGTYTC 3' (SEQ ID NO. 6) (peak 19 reverse); 5' AAYTAYGCNGAYTAYTAYTAY 3' (SEQ ID NO. 7) (peak 24 forward); 5' RTARTARTARTCNGC RTARTT 3' (SEQ ID NO. 8) (peak 24 reverse). All four primers were screened in a PCR assay using all possible pairings (forward and reverse).
- 10 The PCR reaction conditions included 200 ng of genomic DNA, 200 picomoles for each forward and reverse primer, 200  $\mu$ M dNTPs, 1 unit of Vent DNA Polymerase (New England Biolabs) in a 100  $\mu$ l reaction volume. 35 cycles were completed using a 52°C annealing temperature and 1.5 minute extensions at 72°C. The 450 bp product amplified using primers 19 forward and 24 reverse was gel purified and subject to direct DNA
- 15 sequencing which confirmed the inclusion of translated sequence corresponding to peptide peaks 19 and 24 in addition to peak 12. The same DNA was also  $^{32}$ P radiolabeled by random priming using 200  $\mu$ Ci  $\alpha$ - $^{32}$ P[dCTP] at 6000 Ci/mmol (NEN, Boston, MA), 50-100 ng of DNA and the Prime-it II random priming kit (Stratagene) (probel). Unincorporated  $^{32}$ P dNTPs were removed by gel filtration using G-50 Quick-
- 20 spin columns (Roche Biochemicals, New Jersey). Labeling reactions typically yielded approximately 50 ng of radiolabeled DNA with specific activities exceeding 10<sup>9</sup> cpm/ $\mu$ g.

- DNA hybridization probe 2 was initially created by PCR as described above except using degenerate primer 26 5' CARACNTAYACNCCNGGNATGAAY 3' (SEQ ID NO. 9) (peak 26 forward) and 20 picomoles of reverse, non-degenerate primer 54 (5'
- 25 TTCATGGTCGTAACCGCATG 3') (SEQ ID NO. 10); the latter oligonucleotide corresponds to  $\Delta$ 4, 5 DNA sequence 3' of peak 8. Direct sequencing of this PCR fragment confirmed the presence of peak 26 and peak 13 peptides. DNA probe 3 used in DNA southern hybridizations (below) was PCR amplified from genomic DNA using primer 68 (5' TATACACCAGGCATGAACCC 3') (SEQ ID NO. 11) and 74 (5'
- 30 CCCAGTATAAATACTCCAGGT 3') (SEQ ID NO. 12).

*Plaque hybridization screening of F. heparinum genomic library.* A  $\lambda$  ZAP II genomic library (Stratagene) was constructed as described [Sasisekharan, R., Bulmer,

-44-

M., Moremen, K. W., Cooney, C. L., and Langer, R. (1993) *Proc Natl Acad Sci USA* 90, 3660-4]. The amplified library ( $1 \times 10^{10}$  pfu/mL) was plated out at approximately  $1 \times 10^6$  pfu (~50,000 pfu/plate) on 100 x 150 mm LB plates. Plaque lifts on to nylon membranes (Nytran Supercharge, Schleicher and Schuell) and subsequent hybridization  
5 screenings were completed using standard methods and solutions [*Current Protocols in Molecular Biology*, 1987, John Wiley and Sons, New York]. DNA was crosslinked to each filter by UV-irradiation (Stratagene Stratalinker) for 30 seconds at 1200 joules/cm<sup>3</sup>. Hybridizations were carried at 42°C using  $10^7$ - $10^8$  cpm of radiolabeled probe (at approximately 0.25 ng/mL). Low stringency washes were carried out at room  
10 temperature in 2X SSC, 0.1 % SDS; high stringency washes carried out at 58-60°C in 0.2X SSC and 0.1% SDS. Hybridized plaques were visualized by phosphor imaging (Molecular Dynamics) and/or <sup>32</sup>P autoradiography. Tertiary screens of positive clones were completed and the recombinant phage was excised as a double-stranded phagemid (pBluescript) using the ExAssist interference-resistant helper phage and SOLR strain  
15 according to the manufacturer's protocol (Stratagene). Recombinants were characterized by DNA sequencing using both T7 and T3 primers.

*Creation of a flavobacterium Bgl II-EcoRI subgenomic library for isolation of the Δ4, 5' terminus.* 1 μg of genomic DNA was cut with 20 units of *Eco* R1, *Bgl* II, and *Hind* III individually or as double digests. Restriction products were resolved by gel  
20 electrophoresis on 1 % agarose gels run in 1X TAE buffer. Southern DNA hybridizations were completed according to standard protocols [*Current Protocols in Molecular Biology*, 1987, John Wiley and Sons, New York] using <sup>32</sup>P radiolabeled probe 3. Based on this Southern analysis, 5 μg of *Flavobacterium* genomic DNA was digested with *Bgl*-II-*Eco* R1 and the DNA resolved on a preparative 1% agarose gel run under  
25 identical conditions as those described for the analytical gel. DNA ranging from approximately 1-2 kb was gel purified and ligated into pLITMUS as a *Bgl* II-*Eco*RI cassette. Positive clones were identified by PCR colony screening using primers 68 and 74 and confirmed by DNA sequencing.

*PCR cloning of Δ4, 5 gene and recombinant expression in E. coli.* The full-  
30 length glycuronidase gene was directly PCR amplified from genomic DNA using forward primer 85 5' TGTTCTAGACATATGAAATCACTACTCAGTGC (SEQ ID NO. 13) 3' and reverse primer 86 5'

-45-

GTCTCGAGGATCCTTAAGACTGATTAATTGTT 3' (SEQ ID NO. 14) (with *Nde* I and *Xho* I restriction sites denoted in bold), 200ng genomic DNA, and Vent DNA Polymerase for 35 cycles. dA overhangs were generated in a final 10 minute extension at 72°C using AmpliTaq DNA polymerase (Applied Biosystems). PCR products were gel purified, ligated into the TOPO/TA PCR cloning vector (Invitrogen), and transformed into One-shot TOP10 chemically competent cells. Positive clones were identified by blue/white colony selection and confirmed by PCR colony screening. The 1.2kb  $\Delta 4, 5$  gene was subcloned into expression plasmid pET28a (Novagen) as an *Nde* I-*Xho* I cassette. Final expression clones were confirmed by plasmid DNA sequencing.

For the expression of  $\Delta 4, 5$  glycuronidase beginning with M21 ( $\Delta 4, 5^{\Delta 20}$ ), the forward primer 95 5' TGT TCT AGA CAT ATG ACA GTT ACG AAA GGC AA 3' (SEQ ID NO. 15) (also containing an *Nde* I restriction site near its 5' terminus) was used in place of primer 85 (above). 50 ng of the original expression plasmid pET28a/ $\Delta 4, 5$  was used as the DNA template in PCR reactions involving a total of 20 cycles.

Otherwise, cloning was as described for the full-length gene. Both pET28a/ $\Delta 4, 5$  and pET28a $\Delta 4, 5^{\Delta 20}$  plasmids were transformed into BL21 (DE3) for expression as N-terminal 6X His tagged proteins. 1 liter cultures were grown at room temperature (~20°C) in LB media supplemented with 40 µg/mL kanamycin. Protein expression was induced with 500 µM IPTG added at an  $A_{600}$  of 1.0. Induced cultures were allowed to grow for 15 hours (also at room temperature).

*Recombinant  $\Delta 4, 5$  glycuronidase purification.* Bacterial cells were harvested by centrifugation at 6000 x g for 20 minutes and resuspended in 40 mL of binding buffer (50 mM Tris-HCL, pH 7.9, 0.5 M NaCl, and 10 mM imidazole). Lysis was initiated by the addition of 0.1 mg/mL lysozyme (20 minutes at room temperature) followed by intermittent sonication in an ice-water bath using a Misonex XL sonicator at 40-50% output. The crude lysate was fractionated by low-speed centrifugation (18,000 x g; 4°C; 15 minutes) and the supernatant was filtered through a 0.45 micron filter. The 6X-His tag  $\Delta 4, 5$  glycuronidase was purified by  $Ni^{+2}$  chelation chromatography on a 5 mL Hi-Trap column (Pharmacia Biotech, New Jersey) pre-charged with 200 mM  $NiSO_4$  and subsequently equilibrated with binding buffer. The column was run at a flow rate of approximately 3-4 mL/minute that included an intermediate wash step with 50 mM imidazole. The  $\Delta 4, 5$  enzyme was eluted from the column in 5 mL fractions using high

imidazole elution buffer (50 mM Tris-HCL, pH 7.9, 0.5 M NaCl, and 250 mM imidazole). Peak fractions were dialyzed overnight against 4 liters of phosphate buffer (0.1M sodium phosphate, pH 7.0, 0.5 M NaCl) to remove the imidazole.

The 6X His tag was effectively cleaved by adding biotinylated thrombin at 2  
 5 units/milligram of recombinant protein, overnight at 4°C with gentle inversion. Thrombin was captured by binding to streptavidin agarose at 4°C for two hours using the Thrombin Capture Kit (Novagen). The cleaved peptide 5' MGSSHHHHHHSSGLVPR 3' (SEQ ID NO. 16) was removed by final dialysis against a 1000-fold volume of phosphate buffer.

10 Protein concentrations were determined by protein assay (Bio-Rad, Hercules, CA) and confirmed by UV spectroscopy using a theoretical molar extinction coefficient  $\epsilon=88,900$  for  $\Delta 4,5^{\Delta 20}$ . Protein purity was assessed by SDS-PAGE followed by Coomassie Brilliant Blue staining.

*Computational methods.* Signal sequence predictions were made by SignalP  
 15 V1.1 using the von Heijne computational method [Nielsen, H., Engelbrecht, J., Brunak, S., and von Heijne, G., 1997, *Protein Eng* 10, 1-6] with maximum Y and S cutoffs set at 0.36 and 0.88, respectively. Glycuronidase multiple sequence alignments were made from select BLASTP database sequences (with scores exceeding 120 bits and less than 6% gaps) using the CLUSTAL W program (version 1.81) preset to an open gap penalty  
 20 of 10.0, a gap extension penalty of 0.20, and both hydrophilic and residue-specific gap penalties turned on.

*Assay for enzyme activity and determination of kinetic parameters.* Standard reactions were carried out at 30°C and included 100 mM sodium phosphate buffer, pH 6.4, 50mM NaCl, 500 $\mu$ M disaccharide substrate and 200 nM enzyme in a 100  $\mu$ l reaction  
 25 volume. Hydrolysis of heparin disaccharides was determined spectrophotometrically by measuring the loss of the  $\Delta 4, 5$  chromophore measured at 232 nm. Substrate hydrolysis was calculated using the following molar extinction coefficients empirically determined for each disaccharide substrate:  $\Delta\text{UH}_{\text{NAc}}$ ,  $\epsilon_{232}=4,524$ ;  $\Delta\text{UH}_{\text{NAc6S}}$ ,  $\epsilon_{232}=4,300$ ;  $\Delta\text{UH}_{\text{NS}}$ ,  $\epsilon_{232}=6,600$ ;  $\Delta\text{UH}_{\text{NS,6S}}$ ,  $\epsilon_{232}=6,075$ ;  $\Delta\text{UH}_{\text{NH26S}}$ ,  $\epsilon_{232}=4,826$ ;  $\Delta\text{U}_{2\text{S}}\text{H}_{\text{NS}}$ ,  $\epsilon_{232}=4,433$ . Initial  
 30 rates ( $V_0$ ) were extrapolated from linear activities representing <10% substrate turnover and fit to pseudo first-order kinetics. For kinetic experiments, disaccharide concentration for each respective substrate was varied from 48 to 400  $\mu$ M concentrations.  $K_m$  and  $k_{\text{cat}}$



-47-

values were extrapolated from  $V_0$  vs.  $[S]$  curves fit to the Michaelis Menten equation by a non-linear, least squares regression.

For experiments measuring the relative effect of ionic strength on glucuronidase activity, the NaCl concentration was varied from 0.05 to 1 M in 0.1 M sodium phosphate buffer (pH 6.4), 200  $\mu$ M  $\Delta$ UH<sub>NS,6S</sub> and 100  $\mu$ M enzyme under otherwise standard reaction conditions. The effect of pH on catalytic activity was kinetically determined at varying  $\Delta$ UH<sub>NS,6S</sub> concentrations in 0.1 M sodium phosphate buffer at pH 5.2, 5.6, 6.0, 6.4, 6.8, 7.2 and 7.8. Data were fit to Michaelis-Menten kinetics as described above and the relative  $k_{cat}/K_m$  ratios plotted as a function of pH.

*Detection of  $\Delta$ 4, 5 glucuronidase activity by capillary electrophoresis.* 200  $\mu$ g of heparin (Celsus Laboratories) was subject to exhaustive heparinase digestion as described [Venkataraman, G., Shriver, Z., Raman, R., and Sasisekharan, R., 1999, *Science* 286, 537-42] with certain modifications that included a 50 mM PIPES buffer, pH 6.5 with 100 mM NaCl in a 100  $\mu$ l reaction volume. Following heparinase treatment, 25 picomoles of  $\Delta$ 4, 5 glucuronidase was added to one-half of the original reaction (pre-equilibrated at 30°C). 20  $\mu$ l aliquots were removed at 1 minute and 30 minutes and activity quenched by heating at 95°C for 10 minutes. 20  $\mu$ l of the minus  $\Delta$ 4, 5 control (also heated for 10 minutes) was used as the 0 time point. Disaccharide products were resolved by capillary electrophoresis run for 25 minutes under positive polarity mode as previously described [Rhomberg, A. J., Ernst, S., Sasisekharan, R., and Biemann, K., 1998, *Proc Natl Acad Sci USA* 95, 4176-81].

*Molecular mass determinations.* Molecular mass determinations were carried out by MALDI-MS as described [Rhomberg, A. J., Ernst, S., Sasisekharan, R., and Biemann, K., 1998, *Proc Natl Acad Sci USA* 95, 4176-81].

#### **Example 1: Molecular cloning of $\Delta$ 4, 5 glucuronidase gene from *F. heparinum* genome.**

To clone the  $\Delta$ 4, 5 glucuronidase gene, we isolated a series of  $\Delta$ 4, 5 glucuronidase-derived peptides after protease treatment of the purified enzyme. The native enzyme was directly purified from fermentation cultures of *F. heparinum* using a 5-step chromatography scheme as previously described [McLean, M. W., Bruce, J. S., Long, W. F., and Williamson, F. B., 1984, *Eur J Biochem* 145, 607-15]. The extent of

-48-

purity was ultimately characterized by reverse phase chromatography, which indicated a single major peak (**Figure 1A**). We were able to generate a number of peptides by a limited trypsin digestion of the purified enzyme. 26 peptide fragments were resolved by reverse phase chromatography (**Figure 1B**). From these 26, at least eight peptides  
5 (corresponding to major peaks 8, 12, 13, 19, 24, and 26) were of sufficient yield and purity and were selected for protein sequence determination (**Figure 1C**).

Based on this information, we designed degenerate primers corresponding to peaks 19, 24, and 26. These primers were used to PCR amplify  $\Delta 4, 5$  specific sequences to be used as a suitable DNA hybridization probes for screening the *Flavobacterial*  
10 genomic library. A combination of two primer pairs in particular (peak 19 forward and peak 24 reverse) gave a discrete PCR product of approximately 450 base pairs. The translation of the corresponding DNA sequence indicated that it contained the expected amino acid sequence corresponding to peaks 19 and 24. The peak 12 peptide also mapped to this region. We used this discrete PCR amplified DNA fragment (designated  
15 as probe 1, **Figure 2A**) in the initial plaque hybridizations. The most 5' terminal clone obtained in this screening (represented by clone G5A) included approximately one-half of the predicted gene size corresponding to the carboxy terminus of the putative ORF. Invariably, all of the isolated clones possessed an *Eco* R1 site at their respective 5' termini. In an attempt to isolate a clone from the phage library possessing the other half  
20 of the gene, we rescreened additional plaques, this time using a second N-terminal specific DNA hybridization probe (probe 2) in tandem with the original probe 1. This second strategy also failed to yield any clones with the fully-intact  $\Delta 4, 5$  gene. A partial, overlapping clone (G5H), however, did extend the known 5' sequence of  $\Delta 4, 5$  by approximately 540 base pairs.

25 Alternate approaches were taken in an attempt to obtain the 5' terminus of the glycuronidase gene. The size of this missing region was estimated, based on the molecular weight of the native protein, to be approximately 45 amino acids (or 135 base pairs). We completed DNA southern analyses to identify potentially useful DNA restriction sites flanking the 5' end of the  $\Delta 4, 5$  gene (**Figure 2B**). This restriction  
30 mapping ultimately involved the use of the *Eco* R1 site within the gene in conjunction with hybridization probe 3 (whose 3' end lies just 5' to this restriction site) to positively bias our search for the remaining amino terminus. Based on this refined map, we

-49-

successfully isolated and subcloned an approximately 1.5 kb *Bgl* II- *Eco* RI  $\Delta 4, 5$  fragment into pLITMUS. The 5' terminus of the  $\Delta 4, 5$  gene was obtained from direct DNA sequencing of this subgenomic clone.

## 5 Results

A summary of the full-length gene obtained from the two overlapping cloning methods is depicted in Figure 2C. The DNA sequence analysis compiled from the overlapping  $\Delta 4, 5$  clones (and confirmed by direct sequencing of a single PCR amplified genomic clone) is shown in Figure 3. The  $\Delta 4, 5$  coding sequence is comprised of 1209  
10 base pairs corresponding to an ORF that encodes a 402 amino acid protein. The amino acid and nucleotide sequences for the full-length enzyme are given as SEQ ID Nos.:3 and 4, respectively. The predicted molecular weight of 45,621 daltons for the translated protein corresponds very well with an empirical molecular mass of 45,566 daltons for the purified *Flavobacterium* enzyme determined by MALDI-MS. All of the peptides for  
15 which we obtained sequence information map to this  $\Delta 4, 5$  ORF. Based on further primary sequence analyses, we have also identified a likely bacterial signal sequence spanning amino acids 1-20 also possessing a putative cleavage site between residues G20 and M21 (**Figure 4B**). The presence of a markedly hydrophobic amino terminus (see hydropathy plot, **Figure 4A**) and the identification of an AXXA peptidase cleavage  
20 motif further support this assumption [von Heijne, G., 1988, *Biochim Biophys Acta* 947, 307-33].

A search for related sequences in the NCBI protein database led to several functionally related enzymes. In a multiple sequence alignment of our cloned enzyme with select glucuronyl hydrolases, we found a homology that generally corresponded to  
25 upwards of 30% identity and nearly 50% similarity at the primary sequence level (**Figure 4C**). This relatedness spanned most of the enzyme sequence, excluding the N-terminus. Based on this alignment, we found several highly conserved positions within the *F. heparinum*  $\Delta 4, 5$  glucuronidase that included, in particular, several aromatic and acidic residues. Other invariant amino acids of possible catalytic importance include  
30 H115 and R151.

**Example 2: Recombinant expression and purification of the  $\Delta 4, 5$  glucuronidase.**

-50-

Using PCR, we cloned from the *F. heparinum* genome both the full-length enzyme and the “mature” enzyme lacking the N-terminal 20 amino acid signal sequence ( $\Delta 4,5^{\Delta 20}$ ) into a T7-based expression plasmid. Cloning into pET28a permitted the expression of the glycuronidase as an N-terminal 6X His-tag fusion protein. Pilot  
5 expression studies focused on the full-length enzyme. In these initial experiments, we examined several different induction conditions such as temperature, time and length of induction, and even IPTG concentrations. In every case, the full-length enzyme was present nearly exclusively as an insoluble fraction. Attempts to purify the enzyme directly from inclusion bodies and then refold the apparently mis-folded protein were  
10 initially not successful; while solubility was partially achieved by a combined use of detergents (e.g., CHAPS), increasing salt concentrations, and the presence of glycerol, the partially purified enzyme was largely inactive.

A possible explanation for this insolubility points to the presence of a very hydrophobic region within the wild-type protein sequence spanning the first 20 amino  
15 acids. The N-terminal sequence is also predicted to comprise a cleavable prokaryotic signal sequence with the most likely cleavage site occurring between position G20 and M21 (Figure 3). Within this sequence, we also find the alanine repeat 5' AXXAXXAXXXA 3' (SEQ ID NO. 17) that may serve as part of the actual cleavage recognition sequence [von Heijne, G., 1988, *Biochim Biophys Acta* 947, 307-33]. This  
20 signal peptide would indicate a periplasmic location for the glycuronidase with the N-terminus of the secreted (mature) protein beginning with M21. We recombinantly expressed this mature variant ( $\Delta 4,5^{\Delta 20}$ ) in which the signal sequence was replaced entirely by an N-terminal 6X His purification tag. Recombinant expression of the enzyme lacking the presumed signal sequence yielded remarkably different results. In  
25 this case, soluble recombinant expression levels routinely reached several hundred milligrams of protein per liter of induced cells. The specific activity of this enzyme on the heparin disaccharide  $\Delta \text{UH}_{\text{Nac}}$  was likewise robust.

## Results

30 A summary of the expression and purification of  $\Delta 4,5^{\Delta 20}$  is summarized in **Figure 5** and **Table 1**. A two-step purification comprised of  $\text{Ni}^{+2}$  chelation chromatography followed by thrombin cleavage to remove the 6X His purification tag, typically yielded

-51-

over 200 mg of greater than 90% pure enzyme as assessed by SDS-PAGE followed by Coomassie Brilliant Blue staining. An approximately three-fold purification of activity was achieved in a single chromatographic step. Most notably, the specific activity of the recombinant enzyme acting upon  $\Delta\text{UH}_{\text{NAC}}$  far exceeded those values reported in the literature [Warnick, C. T. and Linker, A., 1972, *Biochemistry* 11, 568-72]. While removal of the 6X His tag from the N-terminus of the enzyme was unnecessary for optimal hydrolytic activity, the presence of the histidine tag did appear to instigate protein precipitation over an extended time especially at higher enzyme concentrations. This tag was, therefore removed for all subsequent biochemical experiments. In this manner, the recombinant protein was stable at 4°C for at least two weeks during which time it remained in solution at protein concentrations exceeding 10 mg/mL under the buffer conditions described.

A molecular mass of 44,209 daltons was determined for the recombinant enzyme (i.e.,  $\Delta 4,5^{\Delta 20}$ ) by MALDI-MS. The amino acid and nucleotide sequence for the enzyme which lacks the N-terminal 20 amino acid signal sequence is given as SEQ ID Nos.: 1 and 2, respectively. This empirically-established molecular weight is consistent with its theoretical value of 43,956 Daltons based on its amino acid composition. This value physically differs by 1357 Daltons in comparison to a molecular weight of 45,566 daltons likewise measured for the native enzyme. This mass differential is largely accounted for by the engineered removal in the recombinant protein of the 20 amino acid signal sequence. However, we cannot exclude the possibility of differential posttranslational modifications such as glycosylation largely accounting for the observed differences between the two enzyme populations. Unfortunately, chemical blocking precluded us from determining the N-terminal sequence of the native protein.

25

<i>Purification Step</i>	<i>Protein Yield (mg)</i>	<i>Sp. Activity</i> ( $\mu\text{moles DiS/ min./ mg protein}$ )	<i>% purification</i>
Crude lysate	400	4.7	--
Ni <sup>+2</sup> chromatography	205	12.9	2.7
Thrombin cleavage	205	13.6	2.9

**Table 1.** *Purification summary for the recombinant  $\Delta 4, 5$  glycuronidase.* Specific activities for each fraction were measured using 800ng of protein and 120 $\mu$ M of the unsulfated heparin disaccharide (DiS)  $\Delta$ UH<sub>NAC</sub> in a 100  $\mu$ l reaction volume. The fold purification was calculated relative to the specific activity measured for the crude lysate.

5

**Example 3: Biochemical conditions for optimal enzyme activity.**

To determine the optimal reaction conditions for  $\Delta 4, 5$  glycuronidase activity, we analyzed initial reaction rates as a function of buffer, pH, temperature, and ionic strength (**Figure 6**). For these experiments, we used the disulfated heparin disaccharide substrate  $\Delta$ UH<sub>NS,6S</sub>. Based on what is known about the degradation of heparin/heparan sulfate-like glycosaminoglycans by *flavobacteria* as well as initial biochemical characterization of this and related enzymes [Warnick, C. T. and Linker, A., 1972, *Biochemistry* 11, 568-72], we hypothesized that a heparin disaccharide would be an optimal substrate for the  $\Delta 4, 5$  glycuronidase. Enzyme activity was routinely monitored by a loss of absorbance at 232 nm, corresponding indirectly to the hydrolysis of the uronic acid from the non-reducing end.

10  
15

**Results**

Under these conditions, we observed a NaCl concentration-activity dependence that was optimal between 50 and 100 mM. NaCl concentrations exceeding 100 mM demonstrated a significant and relatively sharply negative effect on specific activity (**Figure 6A**), i.e., with approximately 60% inhibition occurring at 250 mM NaCl relative to 100% activity measured at 100 mM NaCl. The steep transition observed in the NaCl titration curve suggests an important role of ionic interactions in some aspect of enzymatic function.

20  
25

The observed pH profile for the glycuronidase is bell-shaped (**Figure 6C**) with a pH optimum of 6.4. Interestingly, initial reaction rates are significantly reduced at the highest temperatures measured, especially at 42°C (**Figure 6B**). Precubation experiments at 30, 37, and 42°C to assess relative enzyme stabilities at these temperatures, however, indicated no significant change in relative enzyme activities when subsequently measured under the standard 30°C reaction conditions. The results of such an experiment strongly suggest that thermal lability is not the issue.

30

-53-

As a final variable for optimizing  $\Delta 4, 5$  glycuronidase *in vitro* reaction conditions, we also considered any requirement for divalent metal ions. We found no evidence that metals are either required for catalysis or activate the enzyme to any appreciable extent.

5 Having established the reaction conditions for optimal  $\Delta 4, 5$  glycuronidase activity, we next compared the specific activity of the recombinant enzyme ( $\Delta 4, 5^{\Delta 20}$ ) relative to the native enzyme purified directly from *F. heparinum* (Figure 7). The activities of both enzyme fractions were measured in parallel under identical reaction conditions. In this comparison, the recombinant  $\Delta 4, 5$  possessed an approximately three-  
10 fold higher specific glycuronidase activity relative to the native enzyme. These observed rates demonstrate quite clearly that the cloned  $\Delta 4, 5$  enzyme possesses "wild-type" activity that is in no way adversely affected by its recombinant expression in *E. coli*.

#### Example 4: $\Delta 4, 5$ glycuronidase substrate specificity.

15 The specificity of the  $\Delta 4, 5$  glycuronidase acting on various glycosaminoglycan disaccharide substrates was investigated. The various substrates examined included both heparin and chondroitin disaccharides as well as an hyaluronadate. In particular, we considered the possibility of any structural discriminations pertaining to glycosidic linkage position ( $1 \rightarrow 4$  vs.  $1 \rightarrow 3$ ) and relative sulfation state within the disaccharide. For  
20 each substrate, kinetic parameters were determined based on substrate saturation profiles that fit Michaelis-Menten assumptions (Figure 8). These kinetic values are listed in Table 2. For the heparin disaccharides,  $k_{cat}$  values varied significantly from approximately 2 to 15  $\text{sec}^{-1}$ , while the apparent  $K_m$  values for each respective disaccharide were comparable, ranging from approximately 100-300  $\mu\text{M}$ .

25

#### Results

The heparin disaccharide  $\Delta U_{2S}H_{NS}$  was not a substrate at any of the concentrations studied, even following an extended incubation time spanning several hours. For those heparin disaccharides that were hydrolyzed under the conditions tested  
30 and for which kinetic parameters could be determined, an interesting substrate preference was apparent. In this hierarchy and under these conditions, the two disaccharides  $\Delta UH_{NAc}$  and  $\Delta UH_{NAc6S}$  were the best substrates; in comparison,  $\Delta UH_{NH26S}$  and  $\Delta UH_{NS}$

-54-

were less good as substrates. The kinetic values for  $\Delta\text{UH}_{\text{NS},6\text{S}}$  fell roughly in the middle between these two boundaries.

The data show that heparin is a better substrate than chondroitin/dermatan and/or hyaluronan, although these compounds are also substrates. None of the non-heparin  
5 disaccharides were hydrolyzed under the conditions for measuring substrate kinetics. This result indicates an unequivocal discrimination of the  $\Delta 4, 5$  in regard to linkage position, with a strong preference for  $1 \rightarrow 4$  versus  $1 \rightarrow 3$  linkages. At the same time, these disaccharides were slowly hydrolyzed to varying degrees when the enzyme reactions were conducted over a much longer timecourse ( $> 12$  hours) and at considerably higher  
10 enzyme concentrations. After approximately 18 hours, greater than 80% of monosulfated chondroitin disaccharide ( $\Delta\text{UGal}_{\text{Nac}6\text{S}}$ ) was hydrolyzed, whereas the non-sulfated chondroitin ( $\Delta\text{UGal}_{\text{Nac}}$ ) and the hyaluronan disaccharide ( $\Delta\text{UH}$ ) were still present at approximately 40% and 65%, respectively. The importance of the linkage position is, therefore, not absolute. The apparently positive effect of chondroitin 6-O-  
15 sulfation within the galactosamine is consistent with our results for the heparin substrates and provides further evidence for the influence of this position in dictating substrate specificity.

Based on the kinetically defined substrate specificity for the disaccharides, we set out to validate these results while, at the same time, to investigate the utility of the  
20  $\Delta 4, 5$  glycuronidase as an enzymatic tool for HSGAG compositional analyses. In this manner, the  $\Delta 4, 5$  should be very useful in assessing the composition of disaccharides resulting from prior heparinase treatment of heparin/heparan sulfate. For this particular experiment, we pre-treated 200  $\mu\text{g}$  of heparin with a heparinase cocktail. This exhaustive digestion was then directly followed by a relatively short (1 minute) or long  
25 (30 minute)  $\Delta 4, 5$  glycuronidase treatment carried out under optimal reaction conditions. The disaccharide products were then resolved by capillary electrophoresis. The electrophoretic mobility profile for the  $\Delta 4, 5$  treated saccharides were then directly compared to the untreated control (i.e., heparinase treatment only) run under identical conditions (**Figure 9**). 7 disaccharide peaks were present in the capillary  
30 electrophoretogram corresponding to the heparinase only control (A.). A structural assignment for each one of these peaks was made based on previously established compositional analyses. For the most part, the resolution of these  $\Delta 4, 5$  containing



-55-

saccharides was such that each alternating peak (1,3,5,...) corresponded to a disaccharide possessing a 2-O sulfated uronic acid at the non-reducing end. Predictably, the relative amplitude and area of these peaks remained the same, over the entire timecourse of the  $\Delta 4, 5$  preincubation. This unchanging result extended to 18 hours. On the other hand, peaks corresponding to disaccharides lacking the 2-O sulfate were eliminated. Moreover, the relative rates of their disappearances elegantly corresponded to their respective preferences as substrates as determined in the previous kinetic experiment.  $\Delta\text{UH}_{\text{Nac6S}}$  (peak 8) was essentially hydrolyzed within one minute;  $\Delta\text{UH}_{\text{NS,6S}}$  (peak 4) and  $\Delta\text{UH}_{\text{NS}}$  (peak 6) were approximately 75 % and 50% hydrolyzed, respectively. These two latter substrates were completely depleted by 30 minutes.

In addition to the assigned disaccharides, the  $\Delta 4, 5$  glucuronidase also acted on a heparinase-generated tetrasaccharide (identified as peak 2 in **Figure 9**). The assignment of Peak 2 as a tetrasaccharide was confirmed by MALDI-MS indicating a mass of 1036.9 that corresponds to a singly acetylated tetrasaccharide with four sulfates. Disaccharide analysis of this tetrasaccharide further indicated that it does not contain a 2-O sulfate at the non-reducing end. The  $\Delta 4, 5$  enzyme hydrolyzed approximately one-half of the starting material after one minute. The relative rate of hydrolysis for this tetrasaccharide roughly corresponded to the rate observed for the disaccharide  $\Delta\text{UH}_{\text{NS}}$  (peak 6). This exciting result clearly indicates that a longer chain saccharide such as a tetrasaccharide is in fact a substrate for the  $\Delta 4, 5$  catalyzed hydrolysis.

Disaccharide substrates	$k_{\text{cat}}$ ( $\text{sec}^{-1}$ )	$K_m$ ( $\mu\text{M}$ )	$k_{\text{cat}}/K_m$	Relative $k_{\text{cat}}/K_m$
$\Delta\text{UH}_{\text{Nac}}$	$15.3 \pm 0.9$	$283 \pm 31$	0.054	0.49
$\Delta\text{UH}_{\text{Nac, 6S}}$	$11.7 \pm 0.6$	$107 \pm 15$	0.110	1.0
$\Delta\text{UH}_{\text{NS}}$	$4.9 \pm 0.4$	$251 \pm 40$	0.020	0.18
$\Delta\text{UH}_{\text{NS, 6S}}$	$8.8 \pm 0.9$	$334 \pm 57$	0.026	0.24
$\Delta\text{UH}_{\text{NH}_2, 6S}$	$2.4 \pm 0.2$	$235 \pm 40$	0.010	0.09
$\Delta\text{U}_{2\text{S}}\text{H}_{\text{NS}}$	N.A.	N.A.	N.A.	N.A.

**Table 2.** Kinetic parameters for heparin disaccharides.  $k_{\text{cat}}$  and  $K_m$  values were determined from non-linear regression analyses of the Michaelis-Menten curves presented in **Figure 9**. \*N.A., no activity was detected for  $\Delta\text{U}_{2\text{S}}\text{H}_{\text{NS}}$ .

-56-

Each of the foregoing patents, patent applications and references that are recited in this application are herein incorporated in their entirety by reference. Having described the presently preferred embodiments, and in accordance with the present invention, it is believed that other modifications, variations and changes will be suggested to those skilled in the art in view of the teachings set forth herein. It is, therefore, to be understood that all such variations, modifications, and changes are believed to fall within the scope of the present invention as defined by the appended claims.

10           We claim:

-57-

CLAIMS

1. A substantially pure  $\Delta 4,5$  unsaturated glucuronidase.
2. The glucuronidase of claim 1, wherein the glucuronidase is a recombinantly  
5 produced glucuronidase.
3. The glucuronidase of claim 1, wherein the glucuronidase is a synthetic glucuronidase.
4. The glucuronidase of claim 1, wherein the glucuronidase is a peptide having an amino acid sequence of SEQ ID NO:1, or a functional variant thereof.
- 10 5. An isolated polypeptide comprising:  
 $\Delta 4,5$  unsaturated glucuronidase having an amino acid sequence of SEQ ID NO: 1 or a functional variant thereof.
6. The isolated polypeptide of claim 5, wherein the glucuronidase has the amino acid sequence of SEQ ID NO: 1.
- 15 7. A composition comprising, an isolated  $\Delta 4,5$  unsaturated glucuronidase having a higher specific activity than native glucuronidase.
8. The composition of claim 7, wherein the glucuronidase has a specific activity of at least about 60 picomoles of substrate hydrolyzed per minute per picomole of glucuronidase.
- 20 9. The composition of claim 7, wherein the  $\Delta 4,5$  unsaturated glucuronidase has at least about a two fold higher specific activity than native glucuronidase.
10. The composition of claim 7, wherein the  $\Delta 4,5$  unsaturated glucuronidase has at least about a three fold higher specific activity than native glucuronidase.
11. The composition of claim 7, wherein the  $\Delta 4,5$  unsaturated glucuronidase has  
25 at least about a four fold higher specific activity than native glucuronidase.
12. An isolated nucleic acid molecule selected from the group consisting of
  - (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:2, and which code for  $\Delta 4,5$  unsaturated glucuronidase having an amino acid sequence set forth as SEQ ID  
30 NO:1,
  - (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code, and

-58-

(c) complements of (a) or (b).

13. The isolated nucleic acid molecule of claim 12, wherein the isolated nucleic acid molecule codes for SEQ ID NO:1.

14. The isolated nucleic acid molecule of claim 12, wherein the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:2.

15. An expression vector comprising the isolated nucleic acid molecule of claim 10 operably linked to a promoter.

16. A host cell comprising the expression vector of claim 15.

17. An expression vector comprising the isolated nucleic acid molecule of claim 10 14 operably linked to a promoter.

18. A host cell comprising the expression vector of claim 17.

19. A pharmaceutical preparation comprising:

a composition or vector of any of claims 1-15 and a pharmaceutically acceptable carrier.

20. A method of cleaving a glycosaminoglycan, comprising:  
contacting a glycosaminoglycan with the glycuronidase of any one of claims 1-10 in an effective amount to cleave the glycosaminoglycan.

21. A glycosaminoglycan prepared according to the method of claim 20.

22. A method of removing heparin from a heparin containing fluid, comprising:  
20 contacting a heparin containing fluid with the glycuronidase of any one of claims 1-10 in an effective amount to removing heparin from the heparin containing fluid.

23. The method of claim 22, wherein the glycuronidase is immobilized on a solid support.

24. The method of claim 23, wherein heparinase is also immobilized on the solid support.

25. A method of analyzing of a glycosaminoglycan, comprising:  
contacting a glycosaminoglycan with the glycuronidase of any one of claims 1-10 in an effective amount to analyze the glycosaminoglycan.

26. The method of claim 25, wherein the method is a method for identifying the presence of a particular glycosaminoglycan in a sample.

27. The method of claim 25, wherein the method is a method for determining the purity of a glycosaminoglycan in a sample.

28. The method of claim 25, wherein the method is a method for determining the composition of a glycosaminoglycan in a sample.

29. The method of claim 25, wherein the method is a method for determining the sequence of saccharide units in a glycosaminoglycan.

5       30. The method of claim 29, further comprising an additional analytic technique selected from the group consisting of mass spectrometry, NMR spectroscopy, gel electrophoresis, capillary electrophoresis, and HPLC.

31. A method of cleaving a glycosaminoglycan comprised of at least one disaccharide unit, comprising:  
10       contacting a glycosaminoglycan comprised of at least one disaccharide unit with the glycuronidase of any one of claims 1-10 in an effective amount to cleave the glycosaminoglycan.

32. The method of claim 31, wherein the glycosaminoglycan is comprised of  $\Delta\text{UH}_{\text{NAC}}$  disaccharide units.

15       33. The method of claim 31, wherein the glycosaminoglycan is comprised  $\Delta\text{UH}_{\text{NAC},6\text{S}}$  disaccharide units.

34. The method of claim 31, wherein the glycosaminoglycan is comprised of  $\Delta\text{UH}_{\text{NS},6\text{S}}$  disaccharide units.

35. The method of claim 31, wherein the glycosaminoglycan is comprised of  
20  $\Delta\text{UH}_{\text{NS}}$  disaccharide units.

36. The method of claim 31, wherein the glycosaminoglycan length exceeds two saccharide units.

37. The method of claim 30, wherein the glycosaminoglycan does not contain a 2-0 sulfated uronidate.

25       38. The method of claim 30, wherein the glycosaminoglycan is 6-0 sulfated.

39. The method of claim 30, wherein the glycosaminoglycan does contain an N-unsubstituted glycosamine.

40. A method of inhibiting angiogenesis, comprising  
administering to a subject in need thereof an effective amount of the  
30 pharmaceutical preparation of claim 19 for inhibiting angiogenesis.

41. A method of treating cancer, comprising

-60-

administering to a subject in need thereof an effective amount of the pharmaceutical preparation of claim 19 for treating cancer.

42. A method of inhibiting cellular proliferation, comprising administering to a subject in need thereof an effective amount of the pharmaceutical preparation of claim 19 for of inhibiting cellular proliferation.

43. A method of treating a coagulation disorder, comprising administering the composition of claim 19 to a subject in need thereof an effective amount for treat the coagulation disorder.

44. The method of any one of claims 20, 22, or 31, wherein the use of the glycuronidase is concurrent with or follows treatment with heparinase.

45. A pharmaceutical preparation comprising:  
a composition of claim 19 and a pharmaceutically acceptable carrier.

46. A method of inhibiting angiogenesis, comprising administering the composition of claim 21 to a subject in need thereof an effective amount for inhibiting angiogenesis.

47. A method of treating cancer, comprising administering the composition of claim 21 to a subject in need thereof an effective amount for treating cancer.

48. A method of inhibiting cellular proliferation, comprising administering the composition of claim 21 to a subject in need thereof an effective amount for inhibiting cellular proliferation.

49. A method of treating a coagulation disorder, comprising administering the composition of claim 21 to a subject in need thereof an effective amount for treat the coagulation disorder.

25

1/10




Fig. 1A




Fig. 1B

<u>PEAK NO.</u>	<u>PEPTIDE SEQUENCE</u>
8	EFNKPEWFDAAK
12	PGENQFFILK
13	FTLALDTIQYVK
19	VLQRETHQGLTNESAWARGQAWGLYGYTMSYK
24	HSVGALLYNSEIDTPLNYADYYYLEALK
26	TAVIQLTRAAQTYTPGMNPRSVNPDGTVRLAPPR

Fig. 1C

2/10




Fig. 2A




Fig. 2B




Fig. 2C



3/10

aagcgggttttctcgggcatcagacacaactcctttttagttagtattttgggcatagagcgtaaggttaccgg  
 caccaataattaatagcagtaaaaatctattcataacatttttttagttagttacataatttggtttattgacaaaa  
 acgaatgtatagcactccaaccagaatgaatttaggtattgatcaaaatgctatcacttttgattaatcactcat  
 tatttcacaaaaatagatgctgtaatccaaaaaaatcaggcattcaccaattcctaaatgaatatatccgatac  
 ttaaagccttacatctttacactcctaccttcattattaaaaaacaaaacttagatcggaataaatt  
 atgaaatcactactcagtgcgtttgttgcgactattgcattaataggatctgcaaacgggatgacagttacgaaa  
 1 M K S L L S A F V A T I A L I G S A N G M T V T K  
 ggcaacggcgatgactggttaagaaatcaactaaaaccgcagtaatacagttaacacgggctgcacaaacctat  
 26 G N G D D W L K K S T K T A W T O L T R A A T O T Y  
 acaccaggcatgaacccaaggtctgtcaatccggacgggacggtaaggctggccctccccgcgactggaccaca  
 51 I P G M N F R S W N P D G T V R L A P P R D W T T  
 ggtttttcccggaacgttggatggttatgaactatcgggcgataaaaacctggcgccgaagccaaaaga  
 76 G F F P G T L W Y G Y E L S G D K N L A A E A K R  
 tttacccttgcttagatagatacaatatgttaaagatacgcacgacctgggctttatgttgattgttcttat  
 101 F T L A L D T L O Y V K D T H D L G F M L Y C S Y  
 ggcaatgcctaccgtgaaccggagacaagatttacctgaagccattagaaaacgggtgcggccaatttatatgcc  
 126 G N A Y R V T G D K I Y L K P L E N G A A N L Y A  
 cgtttcaataaaaaagtaggggcatccgctcatgggatttcggacactggcaatttcgggaattatagacaac  
 151 R F N K K V G A I R S W D F G H W Q F P V I I D N  
 ctgatgaacctggagttattatactgggcaggaaaggaattcaataagccagaatgggtcgatgctgctaaaaca  
 176 L M N L E Y L Y W A G K E O F N K P E W F D A A K T  
 catggggttacgaccatgaaaaaccatttcagaaaagattatagttcttaccatgtgatcagttacgatacctg  
 201 H A V T T M K N H F R K D Y S S Y H V I S Y D T L  
 tctggaagagtactgcaacgtgaaacccatcagggaacttaccaacgaatcgccctgggcacgggggcaagcctgg  
 226 S G K V L O R E T H O G L T N E S A W A R G O A W  
 ggactttacggctataccatgagctataaggatacgaagacaaaaattcatcgacatgcagagcatatcgct  
 251 G L Y G Y T M S Y K D T K D K K F I E H A E H I A  
 gctttcatcatgaaccacctgcaatgccggcagataaaattccactttgggactttgatgtccacaaccggcag  
 276 A F I M N H P A M P A D K I P L W D F D V H N R D  
 aggtcgccaaggatgcttctgctgctgcagtaattgcttcagccctgctagacctgagcacgcaggtaaaagat  
 301 R S P R D A S A A A V I A S A L L D L S T Q V K D  
 ggtcagaaatatatttaaatttgccgaggatattcctgaaaacattgtcatcagatgaatacctggcgaaacccggc  
 326 G Q K Y F K F A E D I L K T L S S D E Y L A K P G  
 gagaaccagtttttatattgaaacatagtgtaggtgcattgctgtacaattcggaaatcgatacacctttgaat  
 351 E N O F F I L K H S V G A L L Y N S E T D T P L N  
 tatgccgactattactatctggaggctttaaaacgctatgcagagattaaaaaattgacctgaaaacaattaat  
 376 Y A D Y Y Y L E A L K R Y A E I K K I D L K T I N  
 cagtcttaattttaaacacagcattataccaaaacagcaaaggctaccagggttggtagcctttgctgttttg  
 401 Q S STOP  
 atagtttttaaaagaatttaaatcagttattgaacattttggcagggtatttttttaatttggtgaacaagaatt  
 aagaataaaat

Fig. 3

4/10




Fig. 4A




Fig. 4B

5/10

```

1      10      20      30      40      50      60
F. heparinum D4,5 MKSLLSAFVATDALIGSANGMTVTRKNGDMMKKSTKTAMIQETRAAQTYTPGMNRSVN
Bacillus sp. -----MVKQALGDALGITAE-----NKKKFGDRFPHVST
S. pneumoniae -----MMVKQAMTDVAEKTLT-----NKKRPNGRPHVST
S. pyogenes -----MIKKVTPEKPKSPERFLEVPLTKKEEKGQZDKVTKIELNDYFKEDATPAT
A. bisporus --MARPLKTIAEPKQPERFTKEDFISDELTQALDLAKIKVRLNMDYFKEDATPAT
B. halodurans --STHLSNMKAMVALGFLAPSVLAATFPELFSLVFQKILATFNDSPNPT--QVPEQYED
consensus -----1--1-----m-qe-it-ale--lrql--nl--f--d--fp--sd

61      70      80      90      100     110
F. heparinum D4,5 P-DGTVRCAPPRIWTGFFPQTWYV-----VHSGDNLAIEARFTTALDIT---IQYV--
Bacillus sp. G-SNKYVENDNTDWDGFWGCIWLC-----VETGDEQVREGAVRTVAKRRERLDRFEN
S. pneumoniae D-GEHYEENNNNEWNGWNGIWLDC-----VETNDPAFQAAASTVRSQORMEQNIE--
S. pyogenes F-DNVVPTMNNTEFNGWNGIWLDC-----VETNDPAFQAAASTVRSQORMEQNIE--
A. bisporus K-DNOYALMNTETNGWNGIWLDC-----VETNDPAFQAAASTVRSQORMEQNIE--
B. halodurans Q-RAGDMQYFNPTWISGFFPSTIALNTRRTLCGATSRNIGTIANWELGREASRAIET
consensus --dn-y-l-dnteWTngFwsg-Lwla-----yeysgdeayraia-rnvisf-erl-r-le--

120     130     140     150     160
F. heparinum D4,5 --KTHGNYMILYCYGNAIRVTCGRIYKPLENGANITAFKPKVGAIRSDFG---H
Bacillus sp. --EDHHDIGFNLSEAKQWIVKEDSARKLADDAIVKRRVRADAGITQAGPKGDPE
S. pneumoniae --EDHHDIGFNLSEAKQWIVKEDSARKLADDAIVKRRVRADAGITQAGPKGDPE
S. pyogenes --EDHHDIGFNLSEAKQWIVKEDSARKLADDAIVKRRVRADAGITQAGPKGDPE
A. bisporus --EDHHDIGFNLSEAKQWIVKEDSARKLADDAIVKRRVRADAGITQAGPKGDPE
B. halodurans KNSQGFNVLSSTFVVEELAVNPNSFTVTAINSFKLLANKNPTVVGCTRSADAP---D
consensus --ldhHDIGFlysps--a-w-v-xde-ar-a-l-aAdvLm-Rwqek-g-igawg--g--e

170     180     190     200     210     220
F. heparinum D4,5 WQFPIVNNMMLEYKINAKKEFNKPEVDAKTHAVTMMNHFFKDYSSYHVISVDTLS
Bacillus sp. NGGRITNNCCILNPHLWAGEQNGDPSIRRVAAEATLKSRREFLVGGDSSYHVISVDTLS
S. pneumoniae NGGRITNNCCILNPHLWAGEQNGDPSIRRVAAEATLKSRREFLVGGDSSYHVISVDTLS
S. pyogenes NGGRITNNCCILNPHLWAGEQNGDPSIRRVAAEATLKSRREFLVGGDSSYHVISVDTLS
A. bisporus H-VRLTIDCLNPHLWAGEQNGDPSIRRVAAEATLKSRREFLVGGDSSYHVISVDTLS
B. halodurans D-VRLTIDCLNPHLWAGEQNGDPSIRRVAAEATLKSRREFLVGGDSSYHVISVDTLS
consensus PDFOVLDNMNNGEVVRSNSELNNDTLRTGKKHADTMMNHFFKDYSSYHVISVDTLS
--yrifiDcllNI-ILfwageetgdpeyrdva--Ha--s-rnliR-DassyHtfyfdpet

230     240     250     260     270     280
F. heparinum D4,5 LKVLQREHNSHLLPNSAMARQAMTLPNTMYKDTKKKFTSHAEHIAAFIMNHFAA
Bacillus sp. ENALGGHNSHLLPNSAMARQAMTLPNTMYKDTKKKFTSHAEHIAAFIMNHFAA
S. pneumoniae ENALGGHNSHLLPNSAMARQAMTLPNTMYKDTKKKFTSHAEHIAAFIMNHFAA
S. pyogenes ENALGGHNSHLLPNSAMARQAMTLPNTMYKDTKKKFTSHAEHIAAFIMNHFAA
A. bisporus ENALGGHNSHLLPNSAMARQAMTLPNTMYKDTKKKFTSHAEHIAAFIMNHFAA
B. halodurans ENALGGHNSHLLPNSAMARQAMTLPNTMYKDTKKKFTSHAEHIAAFIMNHFAA
consensus GAVTAKRDAQSFARSSVMSRQANGINATMTKELTGKTEYRDTAVRLADYFDH--TEN
G--lrg-ThQGytdStWaRGQaWgiYGfaltyry--d-dyletakrma-yflnr--lp-

290     300     310     320     330     340
F. heparinum D4,5 EKIPLESRDVHNRDRSPRIASAAAMIASALNDLSIQMKD---GQVYKFAEDIKKTLSSE
Bacillus sp. GGVVMDREVQPEPSYRQSSSATAGGLLELASQDDESDPEQRIDAKTTIACRRD
S. pneumoniae GGVVMDREVQPEPSYRQSSSATAGGLLELASQDDESDPEQRIDAKTTIACRRD
S. pyogenes GGVVMDREVQPEPSYRQSSSATAGGLLELASQDDESDPEQRIDAKTTIACRRD
A. bisporus GGVVMDREVQPEPSYRQSSSATAGGLLELASQDDESDPEQRIDAKTTIACRRD
B. halodurans GGVVMDREVQPEPSYRQSSSATAGGLLELASQDDESDPEQRIDAKTTIACRRD
consensus D-v-yWdf--p--eds-rDSAsaiaacglllella-l-e-dpdl:ff--av--mvt-lvd

350     360     370     380     390     400
F. heparinum D4,5 E-LAPFGENQFTLHSGCALYNSGHTPLNLTWVGLDQKVAEIKKIDLRKTINS
Bacillus sp. GGVVMDREVQPEPSYRQSSSATAGGLLELASQDDESDPEQRIDAKTTIACRRD
S. pneumoniae GGVVMDREVQPEPSYRQSSSATAGGLLELASQDDESDPEQRIDAKTTIACRRD
S. pyogenes GGVVMDREVQPEPSYRQSSSATAGGLLELASQDDESDPEQRIDAKTTIACRRD
A. bisporus GGVVMDREVQPEPSYRQSSSATAGGLLELASQDDESDPEQRIDAKTTIACRRD
B. halodurans GGVVMDREVQPEPSYRQSSSATAGGLLELASQDDESDPEQRIDAKTTIACRRD
consensus -ya-r-----a--llrhgvysv--g-avdd--lwGDYyyleAllrl-kI-ngyw-----

```

Fig. 4C

6/10




Fig. 5

7/10




Fig. 6A




Fig. 6B




Fig. 6C

8/10




Fig. 7

9/10




Fig. 8A




Fig. 8B

10/10




Fig. 9



-1-

## SEQUENCE LISTING

<110> Massachusetts Institute of Technology  
 <120> Delta 4,5 Glycuronidase and Uses Thereof  
 <130> M00656/70073 (HCL/MAJ)  
 <160> 23  
 <170> PatentIn version 3.1  
 <210> 1  
 <211> 382  
 <212> PRT  
 <213> Flavobacterium heparinum  
 <400> 1  
 Met Thr Val Thr Lys Gly Asn Gly Asp Asp Trp Leu Lys Lys Ser Thr  
 1 5 10 15  
 Lys Thr Ala Val Ile Gln Leu Thr Arg Ala Ala Gln Thr Tyr Thr Pro  
 20 25 30  
 Gly Met Asn Pro Arg Ser Val Asn Pro Asp Gly Thr Val Arg Leu Ala  
 35 40 45  
 Pro Pro Arg Asp Trp Thr Thr Gly Phe Phe Pro Gly Thr Leu Trp Tyr  
 50 55 60  
 Gly Tyr Glu Leu Ser Gly Asp Lys Asn Leu Ala Ala Glu Ala Lys Arg  
 65 70 75 80  
 Phe Thr Leu Ala Leu Asp Thr Ile Gln Tyr Val Lys Asp Thr His Asp  
 85 90 95  
 Leu Gly Phe Met Leu Tyr Cys Ser Tyr Gly Asn Ala Tyr Arg Val Thr  
 100 105 110  
 Gly Asp Lys Ile Tyr Leu Lys Pro Leu Glu Asn Gly Ala Ala Asn Leu  
 115 120 125  
 Tyr Ala Arg Phe Asn Lys Lys Val Gly Ala Ile Arg Ser Trp Asp Phe  
 130 135 140  
 Gly His Trp Gln Phe Pro Val Ile Ile Asp Asn Leu Met Asn Leu Glu  
 145 150 155 160  
 Tyr Leu Tyr Trp Ala Gly Lys Glu Phe Asn Lys Pro Glu Trp Phe Asp  
 165 170 175  
 Ala Ala Lys Thr His Ala Val Thr Thr Met Lys Asn His Phe Arg Lys  
 180 185 190  
 Asp Tyr Ser Ser Tyr His Val Ile Ser Tyr Asp Thr Leu Ser Gly Lys

-2-

195	200	205
Val Leu Gln Arg Glu Thr His Gln Gly Leu Thr Asn Glu Ser Ala Trp		
210	215	220
Ala Arg Gly Gln Ala Trp Gly Leu Tyr Gly Tyr Thr Met Ser Tyr Lys		
225	230	235 240
Asp Thr Lys Asp Lys Lys Phe Ile Glu His Ala Glu His Ile Ala Ala		
	245	250 255
Phe Ile Met Asn His Pro Ala Met Pro Ala Asp Lys Ile Pro Leu Trp		
	260	265 270
Asp Phe Asp Val His Asn Arg Asp Arg Ser Pro Arg Asp Ala Ser Ala		
	275	280 285
Ala Ala Val Ile Ala Ser Ala Leu Leu Asp Leu Ser Thr Gln Val Lys		
	290	295 300
Asp Gly Gln Lys Tyr Phe Lys Phe Ala Glu Asp Ile Leu Lys Thr Leu		
	305	310 315 320
Ser Ser Asp Glu Tyr Leu Ala Lys Pro Gly Glu Asn Gln Phe Phe Ile		
	325	330 335
Leu Lys His Ser Val Gly Ala Leu Leu Tyr Asn Ser Glu Ile Asp Thr		
	340	345 350
Pro Leu Asn Tyr Ala Asp Tyr Tyr Tyr Leu Glu Ala Leu Lys Arg Tyr		
	355	360 365
Ala Glu Ile Lys Lys Ile Asp Leu Lys Thr Ile Asn Gln Ser		
	370	375 380

<210> 2  
 <211> 1149  
 <212> DNA  
 <213> Flavobacterium heparinum

<400> 2  
 atgacagtta cgaaaggcaa cggc gatgac tggttaaaga aatcaactaa aaccgcagta 60  
 atacagttaa cacgggctgc acaaacctat acaccaggca tgaacccaag gtctgtcaat 120  
 ccggaacggga cggt aaggct ggccctccc cgcgactgga ccacaggttt tttcccggga 180  
 acgttgtggt atggttatga actatcgggc gataaaaacc tggcggccga agccaaaaga 240  
 tttacccttg cottagatac gatacaatat gttaaagata cgcacgaact gggctttatg 300  
 ttgtattggt cttatggcaa tgcctaccgt gtaaccggag acaagattta cctgaagcca 360  
 ttagaaaacg gtgcggccaa tttatatgcc cgtttcaata aaaaagtagg ggccatccgc 420

-3-

```

tcatgggatt tcggacactg gcaatttccg gtaattatag acaacctgat gaacctggag      480
tattttatact gggcaggaaa ggaattcaat aagccagaat ggttcgatgc tgctaaaaca      540
catgcgggta cgaccatgaa aaaccatttc agaaaagatt atagttctta ccatgtgatc      600
agttacgata ccctgtctgg aaaagtactg caacgtgaaa cccatcaggg acttaccaac      660
gaatcggcct gggcacgggg gcaagcctgg ggactttacg gctataccat gagctataag      720
gatacgaaaag acaaaaaaatt catcgaacat gcagagcata tcgctgcttt catcatgaac      780
caccctgcaa tgccggcaga taaaattcca ctttgggact ttgatgtcca caaccgcgac      840
aggtcgccaa gggatgcttc tgctgctgca gtaattgctt cagccctgct agacctgagc      900
acgcaggtaa aagatgggtca gaaatatttt aaatttgccg aggatatacct gaaaacattg      960
tcatcagatg aatacctggc gaaaccggc gagaaccagt tttttatatt gaaacatagt    1020
gtaggtgcat tgctgtacaa ttcggaaatc gatacacctt tgaattatgc cgactattac    1080
tatctggagg ctttaaaacg ctatgcagag attaaaaaaa ttgacctgaa aacaattaat    1140
cagtcttaa                                     1149

```

```

<210> 3
<211> 402
<212> PRT
<213> Flavobacterium heparinum

```

```

<400> 3
Met Lys Ser Leu Leu Ser Ala Phe Val Ala Thr Ile Ala Leu Ile Gly
1           5           10           15

Ser Ala Asn Gly Met Thr Val Thr Lys Gly Asn Gly Asp Asp Trp Leu
20           25           30

Lys Lys Ser Thr Lys Thr Ala Val Ile Gln Leu Thr Arg Ala Ala Gln
35           40           45

Thr Tyr Thr Pro Gly Met Asn Pro Arg Ser Val Asn Pro Asp Gly Thr
50           55           60

Val Arg Leu Ala Pro Pro Arg Asp Trp Thr Thr Gly Phe Phe Pro Gly
65           70           75           80

Thr Leu Trp Tyr Gly Tyr Glu Leu Ser Gly Asp Lys Asn Leu Ala Ala
85           90           95

Glu Ala Lys Arg Phe Thr Leu Ala Leu Asp Thr Ile Gln Tyr Val Lys
100          105          110

Asp Thr His Asp Leu Gly Phe Met Leu Tyr Cys Ser Tyr Gly Asn Ala

```

-4-

115					120					125					
Tyr	Arg	Val	Thr	Gly	Asp	Lys	Ile	Tyr	Leu	Lys	Pro	Leu	Glu	Asn	Gly
130						135					140				
Ala	Ala	Asn	Leu	Tyr	Ala	Arg	Phe	Asn	Lys	Lys	Val	Gly	Ala	Ile	Arg
145					150					155					160
Ser	Trp	Asp	Phe	Gly	His	Trp	Gln	Phe	Pro	Val	Ile	Ile	Asp	Asn	Leu
				165					170					175	
Met	Asn	Leu	Glu	Tyr	Leu	Tyr	Trp	Ala	Gly	Lys	Glu	Phe	Asn	Lys	Pro
			180					185					190		
Glu	Trp	Phe	Asp	Ala	Ala	Lys	Thr	His	Ala	Val	Thr	Thr	Met	Lys	Asn
			195				200						205		
His	Phe	Arg	Lys	Asp	Tyr	Ser	Ser	Tyr	His	Val	Ile	Ser	Tyr	Asp	Thr
						215					220				
Leu	Ser	Gly	Lys	Val	Leu	Gln	Arg	Glu	Thr	His	Gln	Gly	Leu	Thr	Asn
225					230					235					240
Glu	Ser	Ala	Trp	Ala	Arg	Gly	Gln	Ala	Trp	Gly	Leu	Tyr	Gly	Tyr	Thr
				245					250					255	
Met	Ser	Tyr	Lys	Asp	Thr	Lys	Asp	Lys	Lys	Phe	Ile	Glu	His	Ala	Glu
				260				265					270		
His	Ile	Ala	Ala	Phe	Ile	Met	Asn	His	Pro	Ala	Met	Pro	Ala	Asp	Lys
				275			280					285			
Ile	Pro	Leu	Trp	Asp	Phe	Asp	Val	His	Asn	Arg	Asp	Arg	Ser	Pro	Arg
				290			295					300			
Asp	Ala	Ser	Ala	Ala	Ala	Val	Ile	Ala	Ser	Ala	Leu	Leu	Asp	Leu	Ser
305					310					315					320
Thr	Gln	Val	Lys	Asp	Gly	Gln	Lys	Tyr	Phe	Lys	Phe	Ala	Glu	Asp	Ile
				325					330					335	
Leu	Lys	Thr	Leu	Ser	Ser	Asp	Glu	Tyr	Leu	Ala	Lys	Pro	Gly	Glu	Asn
				340				345					350		
Gln	Phe	Phe	Ile	Leu	Lys	His	Ser	Val	Gly	Ala	Leu	Leu	Tyr	Asn	Ser
				355			360						365		
Glu	Ile	Asp	Thr	Pro	Leu	Asn	Tyr	Ala	Asp	Tyr	Tyr	Tyr	Leu	Glu	Ala
				370			375					380			
Leu	Lys	Arg	Tyr	Ala	Glu	Ile	Lys	Lys	Ile	Asp	Leu	Lys	Thr	Ile	Asn
385					390					395					400
Gln	Ser														

&lt;210&gt; 4

-5-

&lt;211&gt; 1209

&lt;212&gt; DNA

&lt;213&gt; Flavobacterium heparinum

&lt;400&gt; 4

```

atgaaatcac tactcagtgc gtttgttgcg actattgcac taataggatc tgcaaacggg      60
atgacagtta cgaaaggcaa cggcgatgac tggttaaaga aatcaactaa aaccgcagta      120
atacagttaa cacgggctgc acaaacctat acaccaggca tgaacccaag gtctgtcaat      180
ccggacggga cggtaaggct ggccccctcc cgcgactgga ccacaggttt tttcccggga      240
acgttgtggt atggttatga actatcgggc gataaaaacc tggcggccga agccaaaaga      300
tttacccttg ccttagatac gatacaatat gttaaagata cgcacgacct gggctttatg      360
ttgtattgtt cttatggcaa tgctaccgt gtaaccggag acaagattta cctgaagcca      420
ttagaaaacg gtgcggccaa tttatatgcc cgtttcaata aaaaagtagg ggccatccgc      480
tcatgggatt tcggacactg gcaatttccg gtaattatag acaacctgat gaacctggag      540
tatttatact gggcaggaaa ggaattcaat aagccagaat ggttcgatgc tgctaaaaca      600
catgcgggta cgaccatgaa aaaccatttc agaaaagatt atagttctta ccatgtgatc      660
agttacgata ccctgtctgg aaaagtactg caacgtgaaa cccatcaggg acttaccaac      720
gaatcggcct gggcacgggg gcaagcctgg ggactttacg gctataccat gagctataag      780
gatacgaaag acaaaaaatt catcgaacat gcagagcata tcgctgcttt catcatgaac      840
caccctgcaa tgccggcaga taaaattcca ctttgggact ttgatgtcca caaccgcgac      900
aggtcgccaa gggatgcttc tgctgctgca gtaattgctt cagccctgct agacctgagc      960
acgcaggtaa aagatgggtca gaaatatttt aaatttgccg aggatatcct gaaaacattg     1020
tcatcagatg aatacctggc gaaaccggc gagaaccagt tttttatatt gaaacatagt     1080
gtaggtgcat tgctgtacaa ttcggaaatc gatacacctt tgaattatgc cgactattac     1140
tatctggagg ctttaaaacg ctatgcagag attaaaaaaaa ttgacctgaa aacaattaat     1200
cagtcttaa                                     1209

```

&lt;210&gt; 5

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Degenerate Primer

-6-

<220>  
 <221> misc\_feature  
 <222> (6)..(6)  
 <223> n = a, g, c or t/u

<220>  
 <221> misc\_feature  
 <222> (15)..(15)  
 <223> n = a, g, c or t/u

<220>  
 <221> misc\_feature  
 <222> (18)..(18)  
 <223> n = a, g, c or t/u

<220>  
 <221> misc\_feature  
 <222> (21)..(21)  
 <223> n = a, g, c or t/u

<400> 5  
 garacncayc arggnytnac naaygar

27

<210> 6  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Degenerate Primer

<220>  
 <221> misc\_feature  
 <222> (7)..(7)  
 <223> n = a, g, c or t/u

<220>  
 <221> misc\_feature  
 <222> (10)..(10)  
 <223> n = a, g, c or t/u

<220>  
 <221> misc\_feature  
 <222> (13)..(13)  
 <223> n = a, g, c or t/u

<220>  
 <221> misc\_feature  
 <222> (22)..(22)  
 <223> n = a, g, c or t/u  
 <400> 6  
 ytcrttngtn arncctgtrt gngtytc

27

-7-

<210> 7  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Degenerate Primer

<220>

<221> misc\_feature  
<222> (9)..(9)  
<223> n = a, g, c or t/u

<400> 7

aaytaygcng aytaytayta y

21

<210> 8  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Degenerate Primer

<220>

<221> misc\_feature  
<222> (13)..(13)  
<223> n = a, g, c or t/u

<400> 8

rtartartar tcngcrtart t

21

<210> 9  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Degenerate Primer

<220>

<221> misc\_feature  
<222> (6)..(6)  
<223> n = a, g, c or t/u

<220>

<221> misc\_feature  
<222> (12)..(12)  
<223> n = a, g, c or t/u

<220>

-8-

<221> misc\_feature  
<222> (15)..(15)  
<223> n = a, g, c or t/u

<220>  
<221> misc\_feature  
<222> (18)..(18)  
<223> n = a, g, c or t/u

<400> 9  
caracntaya cncnggnat gaay

24

<210> 10  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Primer

<400> 10  
ttcatgggtcg taaccgcatg

20

<210> 11  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Primer

<400> 11  
tatacaccag gcatgaaccc

20

<210> 12  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Primer

<400> 12  
cccagtataa atactccagg t

21

<210> 13  
<211> 32  
<212> DNA  
<213> Artificial Sequence



-9-

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 13

tgttctagac atatgaaatc actactcagt gc

32

&lt;210&gt; 14

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 14

gtctcgagga tccttaagac tgattaattg tt

32

&lt;210&gt; 15

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 15

tgttctagac atatgacagt tacgaaaggc aa

32

&lt;210&gt; 16

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Cleaved N-terminal 6X His Tagged Peptide

&lt;400&gt; 16

Met	Gly	Ser	Ser	His	His	His	His	His	His	Ser	Ser	Gly	Leu	Val	Pro
1				5					10				15		

Arg

&lt;210&gt; 17

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

-10-

&lt;220&gt;

&lt;223&gt; Motif Sequence

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (2)..(3)

&lt;223&gt; Xaa = any amino acid

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (5)..(6)

&lt;223&gt; Xaa = any amino acid

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (8)..(11)

&lt;223&gt; Xaa = any amino acid

&lt;400&gt; 17

Ala	Xaa	Xaa	Ala	Xaa	Xaa	Ala	Xaa	Xaa	Xaa	Xaa	Ala
1			5						10		

&lt;210&gt; 18

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Flavobacterium heparinum

&lt;400&gt; 18

Glu	Phe	Asn	Lys	Pro	Glu	Trp	Phe	Asp	Ala	Ala	Lys
1			5						10		

&lt;210&gt; 19

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Flavobacterium heparinum

&lt;400&gt; 19

Pro	Gly	Glu	Asn	Gln	Phe	Phe	Ile	Leu	Lys
1			5						10

&lt;210&gt; 20

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Flavobacterium heparinum

&lt;400&gt; 20

Phe	Thr	Leu	Ala	Leu	Asp	Thr	Ile	Gln	Tyr	Val	Lys
1			5						10		

-11-

<210> 21  
 <211> 32  
 <212> PRT  
 <213> Flavobacterium heparinum

<400> 21  
 Val Leu Gln Arg Glu Thr His Gln Gly Leu Thr Asn Glu Ser Ala Trp  
 1 5 10 15  
 Ala Arg Gly Gln Ala Trp Gly Leu Tyr Gly Tyr Thr Met Ser Tyr Lys  
 20 25 30

<210> 22  
 <211> 28  
 <212> PRT  
 <213> Flavobacterium heparinum

<400> 22  
 His Ser Val Gly Ala Leu Leu Tyr Asn Ser Glu Ile Asp Thr Pro Leu  
 1 5 10 15  
 Asn Tyr Ala Asp Tyr Tyr Tyr Leu Glu Ala Leu Lys  
 20 25

<210> 23  
 <211> 34  
 <212> PRT  
 <213> Flavobacterium heparinum

<400> 23  
 Thr Ala Val Ile Gln Leu Thr Arg Ala Ala Gln Thr Tyr Thr Pro Gly  
 1 5 10 15  
 Met Asn Pro Arg Ser Val Asn Pro Asp Gly Thr Val Arg Leu Ala Pro  
 20 25 30  
 Pro Arg